{
  "id": "weekly-2026-02-09",
  "generatedAt": "2026-02-10T02:52:02.417Z",
  "weekOf": "2026-02-09",
  "crawlSummary": {
    "cms": {
      "ran": true,
      "itemCount": 3,
      "errors": []
    },
    "vendor": {
      "ran": true,
      "itemCount": 9,
      "errors": []
    },
    "payers": {
      "ran": true,
      "itemCount": 52,
      "errors": []
    },
    "nih": {
      "ran": false,
      "itemCount": 0,
      "errors": []
    }
  },
  "submissions": [
    {
      "submissionId": "sub-2026-mlg093hs5hux",
      "source": "cms",
      "type": "coverage_change",
      "title": "Billing and Coding: MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer",
      "summary": "Article update",
      "url": "",
      "detectedAt": "2026-01-30T04:30:07.546Z",
      "triageHint": {
        "daemonScore": 8,
        "reason": "Previously skipped by daemon",
        "suggestedAction": "coverage_update",
        "suggestedTestName": "FoundationOne CDx",
        "confidence": 0.85
      },
      "metadata": {
        "documentId": "",
        "documentType": "Article",
        "contractor": "",
        "effectiveDate": "",
        "version": 1,
        "aiAnalysis": {
          "coverageDecision": "unknown",
          "affectedTests": [
            "FoundationOne CDx",
            "FoundationOne Liquid CDx",
            "Guardant360 CDx",
            "Guardant360 TissueNext",
            "Tempus xT",
            "Tempus xF",
            "Tempus xR",
            "Caris Molecular Intelligence",
            "Oncotype DX"
          ],
          "isMolDXRelevant": true,
          "keyChanges": "This is a billing and coding article for MolDX lab-developed tests for inherited cancer syndromes in patients with cancer, effective January 1, 2026. Specific coverage criteria and billing requirements would be detailed in the full document.",
          "analysisNotes": "This MolDX billing and coding article specifically addresses inherited cancer syndrome testing in cancer patients. While the title suggests focus on hereditary cancer testing rather than somatic tumor profiling, many of the known molecular diagnostic tests could potentially be affected if they include germline variant detection capabilities. The MolDX program oversight indicates this applies to lab-developed tests under Palmetto GBA jurisdiction.",
          "plaCodes": []
        }
      },
      "status": "ignored"
    },
    {
      "submissionId": "sub-2026-mlg093hs6rej",
      "source": "vendor",
      "type": "vendor_clinical_evidence",
      "title": "Exact Sciences: CRANE Study",
      "summary": "First participant enrolled in multi-cancer early detection clinical evaluation in Japan",
      "url": "https://www.exactsciences.com/newsroom",
      "detectedAt": "2026-01-30T18:09:54.447Z",
      "triageHint": {
        "daemonScore": 5,
        "reason": "Previously skipped by daemon",
        "suggestedAction": "data_update",
        "suggestedTestName": "Multi-Cancer Early Detection test",
        "confidence": 0.6
      },
      "metadata": {
        "vendorId": "exact-sciences",
        "vendorName": "Exact Sciences",
        "trialName": "CRANE Study",
        "nctId": null,
        "publication": null,
        "testName": "Multi-Cancer Early Detection test",
        "findings": "First participant enrolled in multi-cancer early detection clinical evaluation in Japan",
        "date": "December 18, 2025"
      },
      "status": "ignored"
    },
    {
      "submissionId": "sub-2026-mlg093hsokhr",
      "source": "vendor",
      "type": "vendor_clinical_evidence",
      "title": "Exact Sciences: CRANE Study",
      "summary": "Multi-Cancer Early Detection Clinical Evaluation in Japan - first participant enrolled",
      "url": "https://www.exactsciences.com/newsroom",
      "detectedAt": "2026-01-30T22:47:14.124Z",
      "triageHint": {
        "daemonScore": 5,
        "reason": "Previously skipped by daemon",
        "suggestedAction": "data_update",
        "suggestedTestName": null,
        "confidence": 0.6
      },
      "metadata": {
        "vendorId": "exact-sciences",
        "vendorName": "Exact Sciences",
        "trialName": "CRANE Study",
        "nctId": null,
        "publication": null,
        "testName": null,
        "findings": "Multi-Cancer Early Detection Clinical Evaluation in Japan - first participant enrolled",
        "date": "December 18, 2025"
      },
      "status": "ignored"
    },
    {
      "submissionId": "sub-2026-mlg093hs5q0e",
      "source": "cms",
      "type": "coverage_change",
      "title": "Billing and Coding: MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer",
      "summary": "Article update",
      "url": "",
      "detectedAt": "2026-02-01T07:39:08.265Z",
      "triageHint": {
        "daemonScore": 8,
        "reason": "",
        "suggestedAction": "coverage_update",
        "suggestedTestName": null,
        "confidence": 0.85
      },
      "metadata": {
        "documentId": "",
        "documentType": "Article",
        "contractor": "",
        "effectiveDate": "",
        "version": 1,
        "aiAnalysis": {
          "coverageDecision": "unknown",
          "affectedTests": [],
          "isMolDXRelevant": true,
          "keyChanges": "This appears to be billing and coding guidance for MolDX lab-developed tests specifically focused on inherited cancer syndromes in cancer patients, updated effective January 2026",
          "analysisNotes": "This is a MolDX billing and coding article for inherited cancer syndrome testing in cancer patients. While it doesn't directly mention the specific ctDNA/MRD tests in the reference list, it could potentially affect germline genetic testing components of comprehensive cancer panels. The document focuses on inherited cancer syndromes rather than somatic tumor profiling or liquid biopsy monitoring. Without access to the full document content, specific coverage criteria and affected tests cannot be determined.",
          "plaCodes": []
        }
      },
      "status": "ignored"
    },
    {
      "submissionId": "sub-2026-mlg093hssqb9",
      "source": "payers",
      "type": "payer_policy_update",
      "title": "Aetna: Tumor Markers (CPB 0352) Updated",
      "summary": "Aetna considers liquid biopsy (up to 50 genes) medically necessary for non-small cell lung cancer patients who are not medically fit for invasive sampling or have insufficient tissue for molecular analysis. Large liquid biopsy panels (greater than 50 genes) are considered experimental, investigational, or unproven for non-small cell lung cancer.",
      "url": "https://www.aetna.com/cpb/medical/data/300_399/0352.html",
      "detectedAt": "2026-02-01T07:45:03.724Z",
      "triageHint": {
        "daemonScore": 8,
        "reason": "",
        "suggestedAction": "coverage_update",
        "suggestedTestName": null,
        "confidence": 0.85
      },
      "metadata": {
        "payerId": "aetna",
        "payerName": "Aetna",
        "policyId": "aetna-cpb-0352",
        "policyName": "Tumor Markers (CPB 0352)",
        "policyType": "tumor_markers",
        "contentType": "html",
        "testsFound": [
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null
        ],
        "isNewPolicy": true,
        "analysis": {
          "summary": "Aetna considers liquid biopsy (up to 50 genes) medically necessary for non-small cell lung cancer patients who are not medically fit for invasive sampling or have insufficient tissue for molecular analysis. Large liquid biopsy panels (greater than 50 genes) are considered experimental, investigational, or unproven for non-small cell lung cancer.",
          "coverageStatus": "conditional",
          "keyConditions": [
            "Non-small cell lung cancer diagnosis",
            "Patient not medically fit for invasive sampling OR insufficient tissue for molecular analysis",
            "Limited to up to 50 genes",
            "Follow-up tissue-based analysis required if oncogenic driver not identified",
            "Specific FDA-approved tests: Guardant360CDx for NSCLC and FoundationOne Liquid CDx for NSCLC and prostate cancer"
          ],
          "testsExplicitlyMentioned": [
            "Liquid biopsy (up to 50 genes) - covered with conditions for NSCLC",
            "Resolution ctDx Lung - covered with conditions for NSCLC",
            "Guardant360CDx - covered for NSCLC",
            "FoundationOne Liquid CDx - covered for NSCLC and prostate cancer"
          ],
          "significantChanges": [
            "Cannot determine changes as this appears to be a current policy snapshot rather than an update document"
          ],
          "confidence": 0.9
        }
      },
      "status": "ignored"
    },
    {
      "submissionId": "sub-2026-mlg093hsk67n",
      "source": "payers",
      "type": "payer_policy_update",
      "title": "Aetna: Pharmacogenetic Testing (CPB 0715) Updated",
      "summary": "Aetna considers several FoundationOne Liquid CDx tests not medically necessary for specific cancer types, stating there is no proven advantage over targeted mutation testing or small targeted panels. The policy also mentions Guardant360 CDx as not medically necessary for certain indications, but does approve ESR1 gene mutation testing using Guardant360 CDx for specific breast cancer cases.",
      "url": "https://www.aetna.com/cpb/medical/data/700_799/0715.html",
      "detectedAt": "2026-02-01T07:45:03.725Z",
      "triageHint": {
        "daemonScore": 8,
        "reason": "",
        "suggestedAction": "coverage_update",
        "suggestedTestName": null,
        "confidence": 0.85
      },
      "metadata": {
        "payerId": "aetna",
        "payerName": "Aetna",
        "policyId": "aetna-cpb-0715",
        "policyName": "Pharmacogenetic Testing (CPB 0715)",
        "policyType": "molecular_oncology",
        "contentType": "html",
        "testsFound": [
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null
        ],
        "isNewPolicy": false,
        "analysis": {
          "summary": "Aetna considers several FoundationOne Liquid CDx tests not medically necessary for specific cancer types, stating there is no proven advantage over targeted mutation testing or small targeted panels. The policy also mentions Guardant360 CDx as not medically necessary for certain indications, but does approve ESR1 gene mutation testing using Guardant360 CDx for specific breast cancer cases.",
          "coverageStatus": "conditional",
          "keyConditions": [
            "FoundationOne Liquid CDx not covered for NSCLC treatment candidacy (osimertinib, erlotinib, gefitinib)",
            "FoundationOne Liquid CDx not covered for melanoma treatment candidacy (encorafenib)",
            "FoundationOne Liquid CDx not covered for ovarian cancer treatment candidacy (rucaparib)",
            "FoundationOne Liquid CDx not covered for NSCLC treatment candidacy (mobocertinib)",
            "Guardant360 CDx approved only for ESR1 gene mutations in advanced/metastatic HER2 negative, ER positive breast cancer for elacestrant treatment",
            "Guardant360 CDx not covered for NSCLC treatment candidacy (osimertinib, amivantamab-vmjw, sotorasib)",
            "Guardant360 CDx not covered for NSCLC treatment candidacy (Enhertu)"
          ],
          "testsExplicitlyMentioned": [
            "FoundationOne Liquid CDx - not covered for multiple indications",
            "Guardant360 CDx - conditionally covered for ESR1 mutations only"
          ],
          "significantChanges": [],
          "confidence": 0.95
        }
      },
      "status": "ignored"
    },
    {
      "submissionId": "sub-2026-mlg093hsse8e",
      "source": "payers",
      "type": "payer_policy_update",
      "title": "Highmark BCBS: Liquid Biopsy Testing - Solid Tumors (L-123) Updated",
      "summary": "Highmark BCBS considers all liquid biopsy testing for solid tumors to be experimental/investigational and therefore non-covered. The policy acknowledges that while analytical validity studies exist for many liquid biopsy assays, data regarding clinical validity and clinical utility is still emerging.",
      "url": "https://secure.highmark.com/ldap/medicalpolicy/wpa-highmark/L-123-006.html",
      "detectedAt": "2026-02-01T07:45:03.726Z",
      "triageHint": {
        "daemonScore": 8,
        "reason": "",
        "suggestedAction": "coverage_update",
        "suggestedTestName": null,
        "confidence": 0.85
      },
      "metadata": {
        "payerId": "highmark",
        "payerName": "Highmark BCBS",
        "policyId": "highmark-l123",
        "policyName": "Liquid Biopsy Testing - Solid Tumors (L-123)",
        "policyType": "liquid_biopsy",
        "contentType": "html",
        "testsFound": [
          null
        ],
        "isNewPolicy": true,
        "analysis": {
          "summary": "Highmark BCBS considers all liquid biopsy testing for solid tumors to be experimental/investigational and therefore non-covered. The policy acknowledges that while analytical validity studies exist for many liquid biopsy assays, data regarding clinical validity and clinical utility is still emerging.",
          "coverageStatus": "not_covered",
          "keyConditions": [
            "All liquid biopsy testing for solid tumors considered experimental/investigational",
            "Insufficient data to determine net health impact",
            "Insufficient data to support analytical and clinical validity",
            "Not generally accepted as standard of care",
            "Providers can bill members directly with advance written notice and agreement"
          ],
          "testsExplicitlyMentioned": [
            "ctDNA testing (mentioned as circulating tumor DNA in context of TRACERx study)",
            "EGFR T790M liquid biopsy testing (referenced in NCCN guidelines but still considered experimental)"
          ],
          "significantChanges": [
            "Cannot determine changes as this appears to be a standalone policy document from July 2018 without comparison to previous versions"
          ],
          "confidence": 0.95
        }
      },
      "status": "ignored"
    },
    {
      "submissionId": "sub-2026-mlg093hs59wi",
      "source": "payers",
      "type": "payer_policy_update",
      "title": "Highmark BCBS: Molecular/Genomic Testing (L-113) Updated",
      "summary": "This policy establishes general criteria for molecular/genomic testing requiring technical validity, clinical utility, and reasonable use, but does not explicitly mention ctDNA, liquid biopsy, or MRD testing. The policy lists many oncology molecular tests as experimental/investigational but none from the ctDNA/liquid biopsy watchlist are specifically named.",
      "url": "https://secure.highmark.com/ldap/medicalpolicy/wpa-highmark/printerfriendly/L-113-009.html",
      "detectedAt": "2026-02-01T07:45:03.726Z",
      "triageHint": {
        "daemonScore": 5,
        "reason": "",
        "suggestedAction": "coverage_update",
        "suggestedTestName": null,
        "confidence": 0.6
      },
      "metadata": {
        "payerId": "highmark",
        "payerName": "Highmark BCBS",
        "policyId": "highmark-l113",
        "policyName": "Molecular/Genomic Testing (L-113)",
        "policyType": "molecular_oncology",
        "contentType": "html",
        "testsFound": [
          null
        ],
        "isNewPolicy": true,
        "analysis": {
          "summary": "This policy establishes general criteria for molecular/genomic testing requiring technical validity, clinical utility, and reasonable use, but does not explicitly mention ctDNA, liquid biopsy, or MRD testing. The policy lists many oncology molecular tests as experimental/investigational but none from the ctDNA/liquid biopsy watchlist are specifically named.",
          "coverageStatus": "unclear",
          "keyConditions": [
            "Technical and clinical validity - test must be accurate, sensitive and specific based on sufficient quality scientific evidence",
            "Clinical utility - healthcare providers can use test results to provide significantly better medical care",
            "Reasonable use - usefulness not significantly offset by negative factors like expense or clinical risk",
            "All three conditions must be met for reimbursement eligibility"
          ],
          "testsExplicitlyMentioned": [],
          "significantChanges": [
            "Cannot determine changes as this appears to be a general policy framework rather than a specific update to ctDNA/liquid biopsy coverage"
          ],
          "confidence": 0.7
        }
      },
      "status": "ignored"
    },
    {
      "submissionId": "sub-2026-mlg093hspfaa",
      "source": "payers",
      "type": "payer_policy_update",
      "title": "Centers for Medicare & Medicaid Services: Next Generation Sequencing (NCD 90.2) Updated",
      "summary": "This Medicare NCD covers Next Generation Sequencing (NGS) as diagnostic laboratory tests for somatic and germline cancer but does not explicitly address ctDNA, liquid biopsy, or MRD testing. Coverage is limited to FDA-approved companion diagnostics for advanced cancer patients and germline testing for breast/ovarian cancer with specific clinical indications.",
      "url": "https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?ncdid=372",
      "detectedAt": "2026-02-01T07:45:03.727Z",
      "triageHint": {
        "daemonScore": 5,
        "reason": "",
        "suggestedAction": "coverage_update",
        "suggestedTestName": null,
        "confidence": 0.6
      },
      "metadata": {
        "payerId": "cms",
        "payerName": "Centers for Medicare & Medicaid Services",
        "policyId": "cms-ncd-90-2",
        "policyName": "Next Generation Sequencing (NCD 90.2)",
        "policyType": "molecular_oncology",
        "contentType": "html",
        "testsFound": [
          null
        ],
        "isNewPolicy": true,
        "analysis": {
          "summary": "This Medicare NCD covers Next Generation Sequencing (NGS) as diagnostic laboratory tests for somatic and germline cancer but does not explicitly address ctDNA, liquid biopsy, or MRD testing. Coverage is limited to FDA-approved companion diagnostics for advanced cancer patients and germline testing for breast/ovarian cancer with specific clinical indications.",
          "coverageStatus": "unclear",
          "keyConditions": [
            "Must be performed in CLIA-certified laboratory",
            "Must be ordered by treating physician",
            "For somatic cancer: patient must have recurrent/relapsed/refractory/metastatic/advanced stage III-IV cancer",
            "Must have FDA approval or clearance as companion in vitro diagnostic",
            "Patient must not have been previously tested with same NGS test for same genetic content",
            "Patient must have decided to seek further cancer treatment",
            "Results must be provided to treating physician with report template specifying treatment options"
          ],
          "testsExplicitlyMentioned": [],
          "significantChanges": [
            "Multiple coding updates and maintenance revisions from 2020-2025",
            "Addition of germline cancer coverage effective January 27, 2020",
            "Various CPT code additions and removals in maintenance updates"
          ],
          "confidence": 0.8
        }
      },
      "status": "ignored"
    },
    {
      "submissionId": "sub-2026-mlg093hsaj4k",
      "source": "vendor",
      "type": "vendor_clinical_evidence",
      "title": "GRAIL: PATHFINDER 2",
      "summary": "Galleri Multi-Cancer Early Detection Blood Test increased cancer detection more than seven-fold when added to USPSTF A and B recommended screenings. More than half of cancers detected by Galleri were early stage. Approximately three-quarters of Galleri-detected cancers do not have recommended screenings. PATHFINDER 2 is the largest U.S. multi-cancer early detection interventional study in the cancer screening population.",
      "url": "https://www.grail.com/press-releases",
      "detectedAt": "2026-02-01T07:55:35.796Z",
      "triageHint": {
        "daemonScore": 5,
        "reason": "",
        "suggestedAction": "data_update",
        "suggestedTestName": "Galleri",
        "confidence": 0.6
      },
      "metadata": {
        "vendorId": "grail",
        "vendorName": "GRAIL",
        "trialName": "PATHFINDER 2",
        "nctId": null,
        "publication": null,
        "testName": "Galleri",
        "findings": "Galleri Multi-Cancer Early Detection Blood Test increased cancer detection more than seven-fold when added to USPSTF A and B recommended screenings. More than half of cancers detected by Galleri were early stage. Approximately three-quarters of Galleri-detected cancers do not have recommended screenings. PATHFINDER 2 is the largest U.S. multi-cancer early detection interventional study in the cancer screening population.",
        "date": "2025-10-17"
      },
      "status": "approved"
    },
    {
      "submissionId": "sub-2026-mlg093hs1373",
      "source": "payers",
      "type": "payer_policy_update",
      "title": "EviCore (Evernorth): Multi-Cancer Early Detection Screening (MOL.TS.396.A) Updated",
      "summary": "EviCore considers multi-cancer early detection (MCED) screening tests using liquid biopsy/ctDNA to be experimental, investigational, or unproven with insufficient evidence to demonstrate clinical utility. The policy explicitly states there is no evidence of clinical validity and clinical utility for ctDNA assays in cancer screening outside of clinical trials.",
      "url": "https://www.evicore.com/sites/default/files/clinical-guidelines/2025-12/MOL.TS_.396.A_Multi-Cancer%20Early%20Detection%20Screening_V1.0.2026_Eff01.01.2026_Pub09.26.2025_Upd12.08.2025_0.pdf",
      "detectedAt": "2026-02-01T07:57:43.058Z",
      "triageHint": {
        "daemonScore": 8,
        "reason": "",
        "suggestedAction": "coverage_update",
        "suggestedTestName": null,
        "confidence": 0.85
      },
      "metadata": {
        "payerId": "evicore",
        "payerName": "EviCore (Evernorth)",
        "policyId": "evicore-mced-2026",
        "policyName": "Multi-Cancer Early Detection Screening (MOL.TS.396.A)",
        "policyType": "liquid_biopsy",
        "contentType": "pdf",
        "testsFound": [],
        "isNewPolicy": true,
        "analysis": {
          "summary": "EviCore considers multi-cancer early detection (MCED) screening tests using liquid biopsy/ctDNA to be experimental, investigational, or unproven with insufficient evidence to demonstrate clinical utility. The policy explicitly states there is no evidence of clinical validity and clinical utility for ctDNA assays in cancer screening outside of clinical trials.",
          "coverageStatus": "not_covered",
          "keyConditions": [
            "Tests are considered Experimental, Investigational, or Unproven (E/I/U)",
            "Insufficient data to demonstrate overall health benefit",
            "Insufficient data to support analytical and clinical validity",
            "Not generally accepted as standard of care",
            "No evidence of clinical utility for ctDNA assays in cancer screening outside clinical trials"
          ],
          "testsExplicitlyMentioned": [
            "ctDNA assays - not covered for screening outside clinical trials",
            "Liquid biopsy tests for early cancer detection - considered experimental/investigational"
          ],
          "significantChanges": [
            "New comprehensive policy specifically addressing MCED screening tests",
            "Clear distinction made between liquid biopsy for screening vs. other purposes",
            "Extensive citation of professional society guidelines opposing screening use"
          ],
          "confidence": 0.95
        }
      },
      "status": "ignored"
    },
    {
      "submissionId": "sub-2026-mlg093hstf7w",
      "source": "payers",
      "type": "payer_policy_update",
      "title": "Carelon (formerly AIM Specialty Health): Somatic Tumor Testing Guidelines Updated",
      "summary": "This document is focused on somatic tumor testing guidelines but the provided content is incomplete, showing only the table of contents and general framework sections without the detailed clinical criteria. No specific mention of ctDNA, liquid biopsy, or MRD testing is found in the available content.",
      "url": "https://guidelines.carelonmedicalbenefitsmanagement.com/wp-content/uploads/2025/08/PDF-Somatic-Tumor-Testing-2025-10-05.pdf",
      "detectedAt": "2026-02-01T07:57:43.059Z",
      "triageHint": {
        "daemonScore": 8,
        "reason": "",
        "suggestedAction": "coverage_update",
        "suggestedTestName": null,
        "confidence": 0.85
      },
      "metadata": {
        "payerId": "carelon",
        "payerName": "Carelon (formerly AIM Specialty Health)",
        "policyId": "carelon-somatic-tumor-2025",
        "policyName": "Somatic Tumor Testing Guidelines",
        "policyType": "molecular_oncology",
        "contentType": "pdf",
        "testsFound": [
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null
        ],
        "isNewPolicy": true,
        "analysis": {
          "summary": "This document is focused on somatic tumor testing guidelines but the provided content is incomplete, showing only the table of contents and general framework sections without the detailed clinical criteria. No specific mention of ctDNA, liquid biopsy, or MRD testing is found in the available content.",
          "coverageStatus": "unclear",
          "keyConditions": [
            "Complete evaluation including history and physical examination required",
            "Anticipated benefit must outweigh potential harms",
            "Must be supported by treatment guidelines and clinical literature",
            "Reasonable likelihood intervention will change management or improve outcomes",
            "Genetic tests not specifically mentioned in guidelines are considered not medically necessary"
          ],
          "testsExplicitlyMentioned": [],
          "significantChanges": [
            "Document shows revised status with effective date of 10/05/2025",
            "Last review date was 04/21/2025",
            "Payer name changed from AIM Specialty Health to Carelon"
          ],
          "confidence": 0.3
        }
      },
      "status": "ignored"
    },
    {
      "submissionId": "sub-2026-mlg093hsxxe5",
      "source": "payers",
      "type": "payer_policy_update",
      "title": "BCBS Michigan: Genetic Testing Including Chromosomal Microarray Updated",
      "summary": "This policy document specifically covers chromosomal microarray (CMA) analysis for pediatric genetic testing in developmental delay, intellectual disability, and autism spectrum disorders. It does not address ctDNA, liquid biopsy, or MRD testing at all.",
      "url": "https://www.bcbsm.com/amslibs/content/dam/public/mpr/mprsearch/pdf/2003173.pdf",
      "detectedAt": "2026-02-01T07:57:43.060Z",
      "triageHint": {
        "daemonScore": 5,
        "reason": "",
        "suggestedAction": "coverage_update",
        "suggestedTestName": null,
        "confidence": 0.6
      },
      "metadata": {
        "payerId": "bcbsm",
        "payerName": "BCBS Michigan",
        "policyId": "bcbsm-genetic-testing-panels",
        "policyName": "Genetic Testing Including Chromosomal Microarray",
        "policyType": "molecular_oncology",
        "contentType": "pdf",
        "testsFound": [
          null
        ],
        "isNewPolicy": true,
        "analysis": {
          "summary": "This policy document specifically covers chromosomal microarray (CMA) analysis for pediatric genetic testing in developmental delay, intellectual disability, and autism spectrum disorders. It does not address ctDNA, liquid biopsy, or MRD testing at all.",
          "coverageStatus": "unclear",
          "keyConditions": [],
          "testsExplicitlyMentioned": [],
          "significantChanges": [],
          "confidence": 1
        }
      },
      "status": "ignored"
    },
    {
      "submissionId": "sub-2026-mlg093hsxtfk",
      "source": "payers",
      "type": "payer_policy_update",
      "title": "BCBS Michigan: Genetic Testing and Counseling Updated",
      "summary": "This is a general genetic testing framework policy that does not specifically address ctDNA, liquid biopsy, or MRD testing. The policy establishes broad criteria for genetic testing of cancer cells, requiring demonstrated clinical utility that leads to treatment changes or improved outcomes.",
      "url": "https://www.bcbsm.com/amslibs/content/dam/public/mpr/mprsearch/pdf/2001657.pdf",
      "detectedAt": "2026-02-01T07:57:43.060Z",
      "triageHint": {
        "daemonScore": 5,
        "reason": "",
        "suggestedAction": "coverage_update",
        "suggestedTestName": null,
        "confidence": 0.6
      },
      "metadata": {
        "payerId": "bcbsm",
        "payerName": "BCBS Michigan",
        "policyId": "bcbsm-genetic-testing-counseling",
        "policyName": "Genetic Testing and Counseling",
        "policyType": "molecular_oncology",
        "contentType": "pdf",
        "testsFound": [
          null
        ],
        "isNewPolicy": true,
        "analysis": {
          "summary": "This is a general genetic testing framework policy that does not specifically address ctDNA, liquid biopsy, or MRD testing. The policy establishes broad criteria for genetic testing of cancer cells, requiring demonstrated clinical utility that leads to treatment changes or improved outcomes.",
          "coverageStatus": "unclear",
          "keyConditions": [
            "Testing must be for conditions with reduced life expectancy or moderate-to-severe morbidity",
            "For cancer cell testing: must establish cell origin when uncertain after standard workup OR provide incremental prognostic information that reclassifies patients into clinically relevant categories with different treatment strategies",
            "Clinical utility must be established - leads to starting effective treatment, discontinuing ineffective treatment, or reclassifying patients in ways that improve outcomes",
            "Test must be FDA cleared/approved or performed in CLIA-certified laboratory"
          ],
          "testsExplicitlyMentioned": [],
          "significantChanges": [
            "Policy effective date is 5/1/25 (future effective date suggests this may be a planned update)"
          ],
          "confidence": 0.3
        }
      },
      "status": "ignored"
    },
    {
      "submissionId": "sub-2026-mlg093hslfgd",
      "source": "payers",
      "type": "payer_policy_update",
      "title": "Blue Shield of California: Oncology: Circulating Tumor DNA and Cells (Liquid Biopsy) Updated",
      "summary": "Blue Shield of California covers liquid biopsy/ctDNA testing for specific advanced cancer types including stage IV lung cancers, metastatic colorectal cancer, advanced pancreatic cancer, and other specified metastatic cancers, with different coverage criteria for broad panels versus single-gene tests. The policy is effective May 1, 2025 and includes comprehensive coverage criteria for various ctDNA applications but does not explicitly mention MRD testing.",
      "url": "https://www.blueshieldca.com/content/dam/bsca/en/provider/docs/medical-policies/Oncology-Circulating-Tumor-DNA-Circulating-Tumor-Cells-Liquid-Biopsy.pdf",
      "detectedAt": "2026-02-01T07:57:43.061Z",
      "triageHint": {
        "daemonScore": 8,
        "reason": "",
        "suggestedAction": "coverage_update",
        "suggestedTestName": null,
        "confidence": 0.85
      },
      "metadata": {
        "payerId": "blueshieldca",
        "payerName": "Blue Shield of California",
        "policyId": "bsca-ctdna-liquid-biopsy",
        "policyName": "Oncology: Circulating Tumor DNA and Cells (Liquid Biopsy)",
        "policyType": "liquid_biopsy",
        "contentType": "pdf",
        "testsFound": [
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null
        ],
        "isNewPolicy": true,
        "analysis": {
          "summary": "Blue Shield of California covers liquid biopsy/ctDNA testing for specific advanced cancer types including stage IV lung cancers, metastatic colorectal cancer, advanced pancreatic cancer, and other specified metastatic cancers, with different coverage criteria for broad panels versus single-gene tests. The policy is effective May 1, 2025 and includes comprehensive coverage criteria for various ctDNA applications but does not explicitly mention MRD testing.",
          "coverageStatus": "conditional",
          "keyConditions": [
            "Stage IV or metastatic lung adenocarcinoma, large cell, squamous cell, or NSCLC NOS",
            "Locally advanced or metastatic pancreatic adenocarcinoma",
            "Metastatic colorectal, gastric, esophageal, or prostate cancer",
            "Stage III or higher cutaneous melanoma",
            "Recurrent ovarian, fallopian tube, or primary peritoneal cancer",
            "Recurrent or stage IV breast cancer",
            "Single gene tests require specific therapy consideration (e.g., EGFR testing when EGFR TKI therapy considered)",
            "Cannot be performed simultaneously with tissue testing except for lung cancer",
            "Tissue-based analysis recommended if ctDNA negative"
          ],
          "testsExplicitlyMentioned": [
            "FoundationOne Liquid CDx - covered for specified conditions",
            "Guardant360 CDx and 83+ gene panel - covered for specified conditions",
            "Tempus xF Liquid Biopsy Panel - covered for specified conditions",
            "Resolution ctDx Lung - covered for advanced/metastatic lung cancers",
            "EGFR, BRAF, KRAS, PIK3CA single gene tests - covered with specific indications"
          ],
          "significantChanges": [
            "New policy with original date June 1, 2023 and effective date May 1, 2025",
            "Expanded coverage to include 20 specific cancer types for broad molecular profiling",
            "California law SB 535 starting July 1, 2022 prohibits prior authorization for biomarker testing for cancer progression and recurrence"
          ],
          "confidence": 0.95
        }
      },
      "status": "ignored"
    },
    {
      "submissionId": "sub-2026-mlg093hsq3yx",
      "source": "payers",
      "type": "payer_policy_update",
      "title": "UnitedHealthcare: Molecular Oncology Testing for Cancer Updated",
      "summary": "UnitedHealthcare provides conditional coverage for liquid biopsy (cfDNA/ctDNA) testing only for non-small cell lung cancer when used for multigene molecular profiling with no more than 50 genes. All MRD (Measurable Residual Disease) assays in solid tumor cancers using any method including ctDNA are explicitly excluded as unproven and not medically necessary.",
      "url": "https://www.uhcprovider.com/content/dam/provider/docs/public/policies/comm-medical-drug/molecular-oncology-testing-for-cancer.pdf",
      "detectedAt": "2026-02-01T07:57:50.790Z",
      "triageHint": {
        "daemonScore": 8,
        "reason": "",
        "suggestedAction": "coverage_update",
        "suggestedTestName": null,
        "confidence": 0.85
      },
      "metadata": {
        "payerId": "uhc",
        "payerName": "UnitedHealthcare",
        "policyId": "uhc-molecular-oncology",
        "policyName": "Molecular Oncology Testing for Cancer",
        "policyType": "molecular_oncology",
        "contentType": "pdf",
        "testsFound": [
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null
        ],
        "isNewPolicy": true,
        "analysis": {
          "summary": "UnitedHealthcare provides conditional coverage for liquid biopsy (cfDNA/ctDNA) testing only for non-small cell lung cancer when used for multigene molecular profiling with no more than 50 genes. All MRD (Measurable Residual Disease) assays in solid tumor cancers using any method including ctDNA are explicitly excluded as unproven and not medically necessary.",
          "coverageStatus": "conditional",
          "keyConditions": [
            "Limited to non-small cell lung cancer only",
            "Multigene molecular profiling with no more than 50 genes",
            "Must be performed using tumor tissue or liquid biopsy (cfDNA/ctDNA)",
            "For more than 50 genes, only when used consistent with FDA Cleared or Approved Companion Diagnostic Testing policy"
          ],
          "testsExplicitlyMentioned": [
            "Invitae Personalized Cancer Monitoring™ - not covered",
            "Signatera™ - not covered",
            "Guardant Reveal™ - not covered",
            "Guardant Shield™ - not covered",
            "RaDaR® - not covered",
            "Haystack MRD™ - not covered"
          ],
          "significantChanges": [
            "Explicit exclusion of all MRD assays in solid tumor cancers whether tumor-informed or tumor-naïve",
            "Limited conditional coverage for liquid biopsy only in lung cancer context",
            "Comprehensive list of excluded ctDNA-based tests including major commercial MRD platforms"
          ],
          "confidence": 0.95
        }
      },
      "status": "ignored"
    },
    {
      "submissionId": "sub-2026-mlg093hsqfg3",
      "source": "payers",
      "type": "payer_policy_update",
      "title": "Cigna: Tumor Profiling (Policy 0520) Updated",
      "summary": "Cigna covers ctDNA/liquid biopsy testing for initial evaluation when tissue testing is not available or contraindicated for advanced/metastatic solid tumors, or when FDA-approved prescribing labels require biomarker confirmation. The policy also allows concurrent tissue-based and ctDNA testing for metastatic breast and lung cancers, and repeat ctDNA testing for advanced solid tumors that have progressed on therapy.",
      "url": "https://static.cigna.com/assets/chcp/pdf/coveragePolicies/medical/mm_0520_coveragepositioncriteria_tumor_profiling.pdf",
      "detectedAt": "2026-02-01T07:57:50.792Z",
      "triageHint": {
        "daemonScore": 8,
        "reason": "",
        "suggestedAction": "coverage_update",
        "suggestedTestName": null,
        "confidence": 0.85
      },
      "metadata": {
        "payerId": "cigna",
        "payerName": "Cigna",
        "policyId": "cigna-0520",
        "policyName": "Tumor Profiling (Policy 0520)",
        "policyType": "molecular_oncology",
        "contentType": "pdf",
        "testsFound": [
          null,
          null,
          null,
          null,
          null,
          null
        ],
        "isNewPolicy": true,
        "analysis": {
          "summary": "Cigna covers ctDNA/liquid biopsy testing for initial evaluation when tissue testing is not available or contraindicated for advanced/metastatic solid tumors, or when FDA-approved prescribing labels require biomarker confirmation. The policy also allows concurrent tissue-based and ctDNA testing for metastatic breast and lung cancers, and repeat ctDNA testing for advanced solid tumors that have progressed on therapy.",
          "coverageStatus": "conditional",
          "keyConditions": [
            "Individual must be candidate for targeted therapy associated with specific tumor biomarker",
            "Results must directly impact clinical decision-making",
            "Testing method must be scientifically valid with proven clinical utility",
            "For initial ctDNA testing: tissue testing must not be available or contraindicated",
            "Advanced or metastatic solid tumors OR FDA-approved prescribing label requires biomarker confirmation",
            "No other tumor biomarker or broad molecular profile panel performed on specimen for same indication",
            "For repeat testing: must have new sample, advanced/metastatic solid tumor, and progression on systemic therapy"
          ],
          "testsExplicitlyMentioned": [
            "Minimal Residual Disease (MRD) testing using high-throughput immunosequencing - covered for multiple myeloma, B-cell ALL, CLL, and peripheral/cutaneous T-cell lymphoma"
          ],
          "significantChanges": [
            "Cannot determine changes as this appears to be a single policy document with effective date 11/9/2025 without comparison to previous version"
          ],
          "confidence": 0.85
        }
      },
      "status": "ignored"
    },
    {
      "submissionId": "sub-2026-mlg093hstrtk",
      "source": "payers",
      "type": "payer_policy_update",
      "title": "Cigna: Genetic Testing (Policy 0052) Updated",
      "summary": "This policy document focuses exclusively on hereditary and multifactorial genetic conditions testing for germline variants passed down through families. It does not address somatic mutations, ctDNA, liquid biopsy, or MRD testing which are used for cancer monitoring and treatment guidance.",
      "url": "https://static.cigna.com/assets/chcp/pdf/coveragePolicies/medical/mm_0052_coveragepositioncriteria_genetic_testing.pdf",
      "detectedAt": "2026-02-01T07:57:50.793Z",
      "triageHint": {
        "daemonScore": 3,
        "reason": "",
        "suggestedAction": "coverage_update",
        "suggestedTestName": null,
        "confidence": 0.35
      },
      "metadata": {
        "payerId": "cigna",
        "payerName": "Cigna",
        "policyId": "cigna-0052",
        "policyName": "Genetic Testing (Policy 0052)",
        "policyType": "molecular_oncology",
        "contentType": "pdf",
        "testsFound": [],
        "isNewPolicy": true,
        "analysis": {
          "summary": "This policy document focuses exclusively on hereditary and multifactorial genetic conditions testing for germline variants passed down through families. It does not address somatic mutations, ctDNA, liquid biopsy, or MRD testing which are used for cancer monitoring and treatment guidance.",
          "coverageStatus": "unclear",
          "keyConditions": [
            "Must be FDA-approved and/or performed in CLIA-accredited laboratory",
            "Results must directly impact clinical decision making",
            "Testing must be for germline/inherited conditions only",
            "Individual must demonstrate signs/symptoms of genetically-linked heritable disease OR have direct risk factor based on family history",
            "Clinical benefit must outweigh potential psychological/medical harm"
          ],
          "testsExplicitlyMentioned": [],
          "significantChanges": [
            "Document shows effective date of 10/11/2025 indicating this is a future policy update",
            "Includes new health equity considerations section addressing disparities in genomic databases"
          ],
          "confidence": 0.9
        }
      },
      "status": "ignored"
    },
    {
      "submissionId": "sub-2026-mlg093hsifoe",
      "source": "payers",
      "type": "payer_policy_update",
      "title": "Anthem/Elevance Health: Molecular Oncology (CG-GENE-14) Updated",
      "summary": "Circulating tumor DNA (ctDNA) testing is covered for guiding targeted cancer therapies in solid tumors, but only when tissue samples are inadequate, unavailable, or of poor quality. The policy explicitly excludes coverage for ctDNA testing to detect tumor recurrence or for cancer susceptibility testing.",
      "url": "https://files.providernews.anthem.com/2003/CG-GENE-14.pdf",
      "detectedAt": "2026-02-01T07:57:50.794Z",
      "triageHint": {
        "daemonScore": 8,
        "reason": "",
        "suggestedAction": "coverage_update",
        "suggestedTestName": null,
        "confidence": 0.85
      },
      "metadata": {
        "payerId": "anthem",
        "payerName": "Anthem/Elevance Health",
        "policyId": "anthem-gene-14",
        "policyName": "Molecular Oncology (CG-GENE-14)",
        "policyType": "molecular_oncology",
        "contentType": "pdf",
        "testsFound": [
          null,
          null
        ],
        "isNewPolicy": true,
        "analysis": {
          "summary": "Circulating tumor DNA (ctDNA) testing is covered for guiding targeted cancer therapies in solid tumors, but only when tissue samples are inadequate, unavailable, or of poor quality. The policy explicitly excludes coverage for ctDNA testing to detect tumor recurrence or for cancer susceptibility testing.",
          "coverageStatus": "conditional",
          "keyConditions": [
            "Must be for guiding targeted cancer therapy in solid tumors",
            "Formalin-fixed paraffin-embedded tumor tissue (FFPET) must be inadequate in quality or quantity or unavailable",
            "Mutation must be established in scientific literature to identify likely responders to targeted therapy",
            "Individual must be a candidate for targeted therapy requiring mutation status prior to treatment"
          ],
          "testsExplicitlyMentioned": [
            "Circulating tumor DNA (ctDNA) testing - conditional coverage",
            "Liquid biopsy - conditional coverage (referenced as synonym for ctDNA)"
          ],
          "significantChanges": [
            "Policy explicitly excludes ctDNA testing for detecting recurrence of solid tumors including colorectal cancer",
            "Clear restriction that ctDNA is secondary to tissue testing when tissue is available"
          ],
          "confidence": 0.95
        }
      },
      "status": "ignored"
    },
    {
      "submissionId": "sub-2026-mlg093hsh842",
      "source": "payers",
      "type": "payer_policy_update",
      "title": "Humana: Liquid Biopsy Updated",
      "summary": "Humana provides very limited coverage for liquid biopsy tests, only covering FDA-approved companion diagnostic tests (like FoundationOne Liquid CDx, Guardant360 CDx) for advanced/metastatic cancer when tissue testing is infeasible. Most ctDNA, liquid biopsy, and MRD tests including Signatera are explicitly excluded as experimental/investigational.",
      "url": "https://assets.humana.com/is/content/humana/Liquid_Biopsypdf",
      "detectedAt": "2026-02-01T07:57:50.795Z",
      "triageHint": {
        "daemonScore": 8,
        "reason": "",
        "suggestedAction": "coverage_update",
        "suggestedTestName": null,
        "confidence": 0.85
      },
      "metadata": {
        "payerId": "humana",
        "payerName": "Humana",
        "policyId": "humana-liquid-biopsy",
        "policyName": "Liquid Biopsy",
        "policyType": "liquid_biopsy",
        "contentType": "pdf",
        "testsFound": [
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null
        ],
        "isNewPolicy": true,
        "analysis": {
          "summary": "Humana provides very limited coverage for liquid biopsy tests, only covering FDA-approved companion diagnostic tests (like FoundationOne Liquid CDx, Guardant360 CDx) for advanced/metastatic cancer when tissue testing is infeasible. Most ctDNA, liquid biopsy, and MRD tests including Signatera are explicitly excluded as experimental/investigational.",
          "coverageStatus": "conditional",
          "keyConditions": [
            "Individual diagnosed with recurrent, relapsed, refractory, metastatic, or advanced stage III or IV cancer",
            "Tissue-based testing is infeasible (quantity not sufficient or invasive biopsy is medically contraindicated)",
            "Individual has not been previously tested for the same genetic content in the primary cancer diagnosis",
            "Individual has decided to seek further cancer treatment",
            "Test must have FDA approval or clearance as a companion in vitro diagnostic",
            "FDA approved or cleared indication for use in that individual's cancer type"
          ],
          "testsExplicitlyMentioned": [
            "FoundationOne Liquid CDx (0239U) - covered under strict conditions",
            "Guardant360 CDx (0242U) - covered under strict conditions",
            "Signatera (0340U) - explicitly not covered",
            "Guardant360 (0326U) - not covered",
            "NavDx (0356U) - not covered"
          ],
          "significantChanges": [
            "Policy effective date 01/25/2024 suggests this is a recent policy",
            "New CPT codes 81462, 81463, 81464 for liquid biopsy panels effective 01/01/2024 are explicitly not covered",
            "Extensive list of excluded tests indicates tightening of coverage criteria"
          ],
          "confidence": 0.95
        }
      },
      "status": "approved"
    },
    {
      "submissionId": "sub-2026-mlg093hsax4m",
      "source": "payers",
      "type": "payer_policy_update",
      "title": "Humana: Comprehensive Genomic Profiling for Solid Tumors Updated",
      "summary": "This policy document does not specifically address ctDNA, liquid biopsy, or MRD testing coverage. While the policy mentions a separate 'Liquid Biopsy' policy in the related policies section, no explicit coverage determinations for liquid biopsy tests are provided in this comprehensive genomic profiling policy.",
      "url": "https://assets.humana.com/is/content/humana/Comprehensive_Genomic_Profiling_and_Genetic_Testing_for_Solid_Tumorspdf",
      "detectedAt": "2026-02-01T07:57:50.796Z",
      "triageHint": {
        "daemonScore": 8,
        "reason": "",
        "suggestedAction": "coverage_update",
        "suggestedTestName": null,
        "confidence": 0.85
      },
      "metadata": {
        "payerId": "humana",
        "payerName": "Humana",
        "policyId": "humana-cgp-solid-tumors",
        "policyName": "Comprehensive Genomic Profiling for Solid Tumors",
        "policyType": "molecular_oncology",
        "contentType": "pdf",
        "testsFound": [
          null,
          null,
          null,
          null,
          null,
          null,
          null
        ],
        "isNewPolicy": true,
        "analysis": {
          "summary": "This policy document does not specifically address ctDNA, liquid biopsy, or MRD testing coverage. While the policy mentions a separate 'Liquid Biopsy' policy in the related policies section, no explicit coverage determinations for liquid biopsy tests are provided in this comprehensive genomic profiling policy.",
          "coverageStatus": "unclear",
          "keyConditions": [
            "Diagnosed with recurrent, relapsed, refractory, metastatic or advanced stage III or IV cancer",
            "Has not previously received comprehensive molecular profiling for the same tumor type",
            "Treatment with anticancer therapy is being considered"
          ],
          "testsExplicitlyMentioned": [
            "Guardant360 (mentioned as example of CGP but no specific coverage determination)"
          ],
          "significantChanges": [
            "Policy effective date is 08/29/2024 indicating this is a recent update",
            "New CPT codes 81457, 81458, 81459 added effective 01/01/2024",
            "Tempus xT and xR tests now separated into distinct DNA and RNA analyses"
          ],
          "confidence": 0.8
        }
      },
      "status": "ignored"
    },
    {
      "submissionId": "sub-2026-mlg093hs0vf4",
      "source": "payers",
      "type": "payer_policy_update",
      "title": "EviCore (Evernorth): Liquid Biopsy Testing (MOL.TS.194.A) Updated",
      "summary": "EviCore covers liquid biopsy testing primarily for FDA-approved companion diagnostic assays when specific criteria are met, and for limited non-CDx uses like Guardant360 LDT for NSCLC when tissue is insufficient. Most other liquid biopsy applications are considered experimental/investigational/unproven and not covered.",
      "url": "https://www.evicore.com/sites/default/files/clinical-guidelines/2025-12/MOL.TS_.194.A_Liquid%20Biopsy%20Testing_V1.0.2026_Eff01.01.2026_Pub09.26.2025_Upd12.09.2025.pdf",
      "detectedAt": "2026-02-01T07:57:50.798Z",
      "triageHint": {
        "daemonScore": 8,
        "reason": "",
        "suggestedAction": "coverage_update",
        "suggestedTestName": null,
        "confidence": 0.85
      },
      "metadata": {
        "payerId": "evicore",
        "payerName": "EviCore (Evernorth)",
        "policyId": "evicore-liquid-biopsy-2026",
        "policyName": "Liquid Biopsy Testing (MOL.TS.194.A)",
        "policyType": "liquid_biopsy",
        "contentType": "pdf",
        "testsFound": [
          null
        ],
        "isNewPolicy": true,
        "analysis": {
          "summary": "EviCore covers liquid biopsy testing primarily for FDA-approved companion diagnostic assays when specific criteria are met, and for limited non-CDx uses like Guardant360 LDT for NSCLC when tissue is insufficient. Most other liquid biopsy applications are considered experimental/investigational/unproven and not covered.",
          "coverageStatus": "conditional",
          "keyConditions": [
            "Cancer diagnosis with FDA-approved companion diagnostic being considered",
            "FDA approval must include member's specific cancer type",
            "No previous somatic/germline testing for the same genetic targets",
            "For non-CDx Guardant360 LDT: metastatic/recurrent NSCLC with insufficient tissue and contraindication to tissue biopsy",
            "For ESR1 testing: metastatic HR+/HER2- breast cancer progressed on endocrine therapy",
            "Qualified laboratory provider per health plan policy"
          ],
          "testsExplicitlyMentioned": [
            "Guardant360 CDx - covered as companion diagnostic",
            "Guardant360 LDT - covered for specific NSCLC criteria",
            "FoundationOne Liquid CDx - covered as companion diagnostic",
            "ESR1 liquid biopsy - covered for specific breast cancer criteria"
          ],
          "significantChanges": [
            "Cannot determine changes as this appears to be initial policy version 1.0.2026",
            "Comprehensive coverage criteria established for companion diagnostics vs non-CDx applications",
            "Most non-companion diagnostic liquid biopsy uses explicitly classified as experimental/investigational"
          ],
          "confidence": 0.9
        }
      },
      "status": "ignored"
    },
    {
      "submissionId": "sub-2026-mlg093hsteyp",
      "source": "payers",
      "type": "payer_policy_update",
      "title": "Carelon (formerly AIM Specialty Health): Genetic Liquid Biopsy in Cancer Management (UC0126) Updated",
      "summary": "Carelon provides conditional coverage for genetic liquid biopsy testing in cancer management, including ctDNA and MRD testing, with specific criteria for different cancer sites and clinical scenarios. The policy establishes evidence-based guidelines for when liquid biopsy testing is medically necessary, covering applications like variant detection, treatment monitoring, and minimal residual disease assessment.",
      "url": "https://guidelines.carelonmedicalbenefitsmanagement.com/wp-content/uploads/2025/11/PDF-Genetic-Liquid-Biopsy-in-the-Management-of-Cancer-and-Cancer-Surveillance-2025-11-15-UC0126.pdf",
      "detectedAt": "2026-02-01T07:57:50.799Z",
      "triageHint": {
        "daemonScore": 8,
        "reason": "",
        "suggestedAction": "coverage_update",
        "suggestedTestName": null,
        "confidence": 0.85
      },
      "metadata": {
        "payerId": "carelon",
        "payerName": "Carelon (formerly AIM Specialty Health)",
        "policyId": "carelon-liquid-biopsy-2025",
        "policyName": "Genetic Liquid Biopsy in Cancer Management (UC0126)",
        "policyType": "liquid_biopsy",
        "contentType": "pdf",
        "testsFound": [
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null
        ],
        "isNewPolicy": true,
        "analysis": {
          "summary": "Carelon provides conditional coverage for genetic liquid biopsy testing in cancer management, including ctDNA and MRD testing, with specific criteria for different cancer sites and clinical scenarios. The policy establishes evidence-based guidelines for when liquid biopsy testing is medically necessary, covering applications like variant detection, treatment monitoring, and minimal residual disease assessment.",
          "coverageStatus": "conditional",
          "keyConditions": [
            "Testing must have established analytical and clinical validity",
            "Must be performed in appropriately certified laboratory",
            "Cancer site-specific criteria must be met",
            "Repeated testing limited to evaluation following intervention or change in clinical status",
            "General criteria for genetic liquid biopsy testing must be satisfied",
            "Individual circumstances and clinical judgment considered"
          ],
          "testsExplicitlyMentioned": [
            "ctDNA testing",
            "Minimal Residual Disease (MRD) testing",
            "Genetic liquid biopsy testing"
          ],
          "significantChanges": [
            "Updated codes effective 01/01/2026",
            "Document updated with effective date 11/15/2025",
            "Last review date 04/21/2025 indicates recent policy review"
          ],
          "confidence": 0.85
        }
      },
      "status": "ignored"
    },
    {
      "submissionId": "sub-2026-mlg093hslaxb",
      "source": "payers",
      "type": "payer_policy_update",
      "title": "BCBS Michigan: Circulating Tumor DNA Updated",
      "summary": "BCBS Michigan covers ctDNA and liquid biopsy testing for selecting targeted therapy in advanced solid cancers when specific criteria are met, but considers MRD testing and cancer screening investigational. Coverage requires advanced/metastatic cancer, inability to perform tissue testing OR FDA-approved companion diagnostic status, and no prior testing with the same panel.",
      "url": "https://www.bcbsm.com/amslibs/content/dam/public/mpr/mprsearch/pdf/2002479.pdf",
      "detectedAt": "2026-02-01T07:57:50.801Z",
      "triageHint": {
        "daemonScore": 8,
        "reason": "",
        "suggestedAction": "coverage_update",
        "suggestedTestName": null,
        "confidence": 0.85
      },
      "metadata": {
        "payerId": "bcbsm",
        "payerName": "BCBS Michigan",
        "policyId": "bcbsm-ctdna",
        "policyName": "Circulating Tumor DNA",
        "policyType": "ctdna",
        "contentType": "pdf",
        "testsFound": [
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null
        ],
        "isNewPolicy": true,
        "analysis": {
          "summary": "BCBS Michigan covers ctDNA and liquid biopsy testing for selecting targeted therapy in advanced solid cancers when specific criteria are met, but considers MRD testing and cancer screening investigational. Coverage requires advanced/metastatic cancer, inability to perform tissue testing OR FDA-approved companion diagnostic status, and no prior testing with the same panel.",
          "coverageStatus": "conditional",
          "keyConditions": [
            "Advanced solid cancers (metastatic, inoperable locally advanced, refractory, recurrent, or stages III-IV)",
            "For selecting FDA-approved targeted therapeutic options",
            "No previous testing with same liquid biopsy panel unless new primary cancer or relapse",
            "Clinical documentation that tissue-based testing cannot be performed OR FDA-approved companion diagnostic device",
            "Must be FDA-approved companion diagnostic for PLA tests"
          ],
          "testsExplicitlyMentioned": [
            "Galleri - explicitly excluded as investigational for cancer screening",
            "MRD testing - explicitly excluded as investigational"
          ],
          "significantChanges": [
            "Policy effective date shows 1/1/26 suggesting this is a future update",
            "Clear distinction between established codes (covered) and investigational codes",
            "Specific exclusion of MRD testing as investigational",
            "Addition of multiple PLA test codes in both covered and investigational categories"
          ],
          "confidence": 0.95
        }
      },
      "status": "approved"
    },
    {
      "submissionId": "sub-2026-mlg093hsl2rv",
      "source": "payers",
      "type": "payer_policy_update",
      "title": "BCBS Michigan: Genetic Cancer Susceptibility Updated",
      "summary": "This policy covers genetic cancer susceptibility panels but only limited panels where the member meets criteria for specific gene variants established in other policies. One related policy specifically mentions 'Circulating Tumor DNA Management of Non-Small-Cell Lung Cancer (Liquid Biopsy)' but coverage details are not provided in this document.",
      "url": "https://www.bcbsm.com/amslibs/content/dam/public/mpr/mprsearch/pdf/2032136.pdf",
      "detectedAt": "2026-02-01T07:57:50.802Z",
      "triageHint": {
        "daemonScore": 8,
        "reason": "",
        "suggestedAction": "coverage_update",
        "suggestedTestName": null,
        "confidence": 0.85
      },
      "metadata": {
        "payerId": "bcbsm",
        "payerName": "BCBS Michigan",
        "policyId": "bcbsm-cancer-susceptibility",
        "policyName": "Genetic Cancer Susceptibility",
        "policyType": "molecular_oncology",
        "contentType": "pdf",
        "testsFound": [
          null,
          null,
          null
        ],
        "isNewPolicy": true,
        "analysis": {
          "summary": "This policy covers genetic cancer susceptibility panels but only limited panels where the member meets criteria for specific gene variants established in other policies. One related policy specifically mentions 'Circulating Tumor DNA Management of Non-Small-Cell Lung Cancer (Liquid Biopsy)' but coverage details are not provided in this document.",
          "coverageStatus": "unclear",
          "keyConditions": [
            "Limited genetic cancer susceptibility panels only where member meets criteria in other established policies",
            "Must include only gene variants for which specific criteria are met in related policies",
            "All other genetic cancer susceptibility panel testing considered experimental/investigational"
          ],
          "testsExplicitlyMentioned": [
            "Circulating Tumor DNA Management of Non-Small-Cell Lung Cancer (Liquid Biopsy) - referenced as related policy but coverage details not specified"
          ],
          "significantChanges": [
            "Policy effective date shows future date of 11/1/25, suggesting this may be an upcoming policy version"
          ],
          "confidence": 0.3
        }
      },
      "status": "ignored"
    },
    {
      "submissionId": "sub-2026-mlg093hsugmr",
      "source": "payers",
      "type": "payer_policy_update",
      "title": "Blue Shield of California: Oncology: Algorithmic Testing Updated",
      "summary": "This Blue Shield of California policy document focuses on tissue-based algorithmic tests for various cancer types but does not explicitly address ctDNA, liquid biopsy, or MRD testing. The policy appears to be specific to genomic and proteomic tests performed on tumor tissue samples rather than blood-based liquid biopsies.",
      "url": "https://www.blueshieldca.com/content/dam/bsca/en/provider/docs/medical-policies/Oncology-Algorithmic-Testing.pdf",
      "detectedAt": "2026-02-01T07:57:50.804Z",
      "triageHint": {
        "daemonScore": 8,
        "reason": "",
        "suggestedAction": "coverage_update",
        "suggestedTestName": null,
        "confidence": 0.85
      },
      "metadata": {
        "payerId": "blueshieldca",
        "payerName": "Blue Shield of California",
        "policyId": "bsca-algorithmic-testing",
        "policyName": "Oncology: Algorithmic Testing",
        "policyType": "molecular_oncology",
        "contentType": "pdf",
        "testsFound": [
          null,
          null,
          null
        ],
        "isNewPolicy": true,
        "analysis": {
          "summary": "This Blue Shield of California policy document focuses on tissue-based algorithmic tests for various cancer types but does not explicitly address ctDNA, liquid biopsy, or MRD testing. The policy appears to be specific to genomic and proteomic tests performed on tumor tissue samples rather than blood-based liquid biopsies.",
          "coverageStatus": "unclear",
          "keyConditions": [],
          "testsExplicitlyMentioned": [],
          "significantChanges": [
            "This appears to be a new policy with original date of August 1, 2023 and effective date of May 1, 2025"
          ],
          "confidence": 0.9
        }
      },
      "status": "ignored"
    },
    {
      "submissionId": "sub-2026-mlg093hs8lit",
      "source": "payers",
      "type": "payer_policy_update",
      "title": "Blue Shield of California: Oncology: Molecular Analysis for Solid Tumors and Hematologic Malignancies Updated",
      "summary": "The policy provides conditional coverage for several ctDNA/liquid biopsy MRD tests, with evidence-based tests like Signatera, Guardant Reveal, and Guardant360 Response having established coverage criteria, while emerging tests like COLVERA and Invitae PCM have more limited coverage. Coverage is generally limited to specific clinical scenarios involving recurrent, metastatic, or advanced cancers where patients are seeking further treatment.",
      "url": "https://www.blueshieldca.com/content/dam/bsca/en/provider/docs/medical-policies/Oncology-Molecular-Analysis-Solid-Tumors-Hematologic-Malignancies.pdf",
      "detectedAt": "2026-02-01T07:57:50.805Z",
      "triageHint": {
        "daemonScore": 8,
        "reason": "",
        "suggestedAction": "coverage_update",
        "suggestedTestName": null,
        "confidence": 0.85
      },
      "metadata": {
        "payerId": "blueshieldca",
        "payerName": "Blue Shield of California",
        "policyId": "bsca-molecular-analysis-tumors",
        "policyName": "Oncology: Molecular Analysis for Solid Tumors and Hematologic Malignancies",
        "policyType": "molecular_oncology",
        "contentType": "pdf",
        "testsFound": [
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null,
          null
        ],
        "isNewPolicy": true,
        "analysis": {
          "summary": "The policy provides conditional coverage for several ctDNA/liquid biopsy MRD tests, with evidence-based tests like Signatera, Guardant Reveal, and Guardant360 Response having established coverage criteria, while emerging tests like COLVERA and Invitae PCM have more limited coverage. Coverage is generally limited to specific clinical scenarios involving recurrent, metastatic, or advanced cancers where patients are seeking further treatment.",
          "coverageStatus": "conditional",
          "keyConditions": [
            "Diagnosis of recurrent, relapsed, refractory, metastatic, or advanced stage III/IV cancer",
            "Member is seeking further cancer treatment (e.g., therapeutic chemotherapy)",
            "Evidence-based MRD tests have broader coverage than emerging evidence tests",
            "HPV-related tumors may qualify for NavDx testing",
            "Specific coverage varies by test classification (Evidence-Based vs Emerging Evidence)"
          ],
          "testsExplicitlyMentioned": [
            "Signatera (Evidence-Based Solid Tumor MRD)",
            "Guardant Reveal (Evidence-Based Solid Tumor MRD)",
            "Guardant360 Response (Evidence-Based Solid Tumor MRD)",
            "COLVERA (Emerging Evidence Solid Tumor MRD)",
            "Invitae Personalized Cancer Monitoring (Emerging Evidence Solid Tumor MRD)",
            "NavDx (HPV-Related Solid Tumor MRD)"
          ],
          "significantChanges": [
            "Policy appears to be new/updated with effective date of May 1, 2025",
            "Structured classification of MRD tests into Evidence-Based vs Emerging Evidence categories",
            "Inclusion of multiple liquid biopsy platforms with specific CPT codes"
          ],
          "confidence": 0.9
        }
      },
      "status": "ignored"
    },
    {
      "submissionId": "sub-2026-mlg093hs5u42",
      "source": "cms",
      "type": "coverage_change",
      "title": "Billing and Coding: MolDX: Pharmacogenomics Testing",
      "summary": "Article update",
      "url": "",
      "detectedAt": "2026-02-05T19:57:51.054Z",
      "triageHint": {
        "daemonScore": 8,
        "reason": "",
        "suggestedAction": "coverage_update",
        "suggestedTestName": null,
        "confidence": 0.85
      },
      "metadata": {
        "documentId": "",
        "documentType": "Article",
        "contractor": "",
        "effectiveDate": "",
        "version": 1,
        "aiAnalysis": {
          "coverageDecision": "unknown",
          "affectedTests": [],
          "isMolDXRelevant": true,
          "keyChanges": "This appears to be a billing and coding article for MolDX pharmacogenomics testing with an effective date of February 5, 2026, indicating future policy implementation",
          "analysisNotes": "This is a MolDX billing and coding article specifically focused on pharmacogenomics testing rather than the ctDNA, liquid biopsy, MRD, or tumor profiling tests in the search list. Pharmacogenomics tests analyze genetic variations that affect drug metabolism and response, which is a different category from the oncology molecular diagnostics tests specified. Without access to the full article content, specific coverage criteria, PLA codes, and billing requirements cannot be determined. The future effective date suggests this may contain updated billing guidance for pharmacogenomics testing under the MolDX program.",
          "plaCodes": []
        }
      },
      "status": "ignored"
    },
    {
      "submissionId": "sub-2026-mlg093hs1gec",
      "source": "vendor",
      "type": "vendor_new_indication",
      "title": "Guardant Health: Reveal Test expands to Late-Stage Therapy Response Monitoring",
      "summary": "New indication: Late-Stage Therapy Response Monitoring",
      "url": "https://guardanthealth.com/newsroom/press-releases",
      "detectedAt": "2026-02-05T20:00:48.733Z",
      "triageHint": {
        "daemonScore": 8,
        "reason": "",
        "suggestedAction": "data_update",
        "suggestedTestName": "Reveal Test",
        "confidence": 0.85
      },
      "metadata": {
        "vendorId": "guardant",
        "vendorName": "Guardant Health",
        "testName": "Reveal Test",
        "indication": "Late-Stage Therapy Response Monitoring",
        "date": null
      },
      "status": "ignored"
    },
    {
      "submissionId": "sub-2026-mlg093hstn52",
      "source": "vendor",
      "type": "vendor_clinical_evidence",
      "title": "Veracyte: Clinical Evidence",
      "summary": "First publications using Afirma GRID Research Tool to help usher in next generation of thyroid nodule testing, leveraging whole transcriptome-derived data to identify molecular classifiers and signatures differentiating thyroid cancer risk groups",
      "url": "https://investor.veracyte.com/rss/news-releases.xml",
      "detectedAt": "2026-02-05T20:00:48.738Z",
      "triageHint": {
        "daemonScore": 3,
        "reason": "",
        "suggestedAction": "data_update",
        "suggestedTestName": "Afirma GRID",
        "confidence": 0.35
      },
      "metadata": {
        "vendorId": "veracyte",
        "vendorName": "Veracyte",
        "trialName": null,
        "nctId": null,
        "journal": null,
        "pmid": null,
        "doi": null,
        "firstAuthor": null,
        "publicationDate": null,
        "testName": "Afirma GRID",
        "cancerType": "thyroid",
        "findings": "First publications using Afirma GRID Research Tool to help usher in next generation of thyroid nodule testing, leveraging whole transcriptome-derived data to identify molecular classifiers and signatures differentiating thyroid cancer risk groups"
      },
      "status": "ignored"
    },
    {
      "submissionId": "sub-2026-mlg093hs1rk1",
      "source": "vendor",
      "type": "vendor_clinical_evidence",
      "title": "GRAIL: PATHFINDER 2",
      "summary": "Galleri Multi-Cancer Early Detection Blood Test Increased Cancer Detection More Than Seven-Fold When Added to USPSTF A and B Recommended Screenings. More Than Half of Cancers Detected by Galleri Were Early Stage. Approximately Three-Quarters of Galleri-Detected Cancers Do Not Have Recommended Screenings. PATHFINDER 2 is the Largest U.S. Multi-Cancer Early Detection (MCED) Interventional Study in the Cancer Screening Population",
      "url": "https://www.grail.com/press-releases",
      "detectedAt": "2026-02-05T20:04:56.155Z",
      "triageHint": {
        "daemonScore": 3,
        "reason": "",
        "suggestedAction": "data_update",
        "suggestedTestName": "Galleri",
        "confidence": 0.35
      },
      "metadata": {
        "vendorId": "grail",
        "vendorName": "GRAIL",
        "trialName": "PATHFINDER 2",
        "nctId": null,
        "journal": null,
        "pmid": null,
        "doi": null,
        "firstAuthor": null,
        "publicationDate": null,
        "testName": "Galleri",
        "cancerType": "multi-cancer",
        "findings": "Galleri Multi-Cancer Early Detection Blood Test Increased Cancer Detection More Than Seven-Fold When Added to USPSTF A and B Recommended Screenings. More Than Half of Cancers Detected by Galleri Were Early Stage. Approximately Three-Quarters of Galleri-Detected Cancers Do Not Have Recommended Screenings. PATHFINDER 2 is the Largest U.S. Multi-Cancer Early Detection (MCED) Interventional Study in the Cancer Screening Population"
      },
      "status": "ignored"
    },
    {
      "submissionId": "sub-2026-mlg093hsfj0a",
      "source": "vendor",
      "type": "vendor_clinical_evidence",
      "title": "Quest Diagnostics: Clinical Evidence",
      "summary": "Data to be presented at 2026 ASCO Gastrointestinal Cancers Symposium",
      "url": "https://newsroom.questdiagnostics.com/press-releases",
      "detectedAt": "2026-02-05T20:04:56.157Z",
      "triageHint": {
        "daemonScore": 3,
        "reason": "",
        "suggestedAction": "data_update",
        "suggestedTestName": "Haystack MRD®",
        "confidence": 0.35
      },
      "metadata": {
        "vendorId": "quest",
        "vendorName": "Quest Diagnostics",
        "trialName": null,
        "nctId": null,
        "journal": null,
        "pmid": null,
        "doi": null,
        "firstAuthor": null,
        "publicationDate": "2026",
        "testName": "Haystack MRD®",
        "cancerType": "gastrointestinal cancers",
        "findings": "Data to be presented at 2026 ASCO Gastrointestinal Cancers Symposium"
      },
      "status": "approved",
      "triageNote": "Auto-approved: ASCO GI 2026 abstracts added to mrd-1 numPublicationsNotes"
    },
    {
      "submissionId": "sub-2026-mlg093hs8c6b",
      "source": "vendor",
      "type": "vendor_coverage_announcement",
      "title": "Personalis Receives Medicare Coverage for MRD Assay in Breast Cancer",
      "summary": "Medicare provides coverage for Personalis MRD assay in breast cancer",
      "url": "https://www.personalis.com/news",
      "detectedAt": "2026-02-05T20:04:56.158Z",
      "triageHint": {
        "daemonScore": 8,
        "reason": "",
        "suggestedAction": "coverage_update",
        "suggestedTestName": "MRD Assay",
        "confidence": 0.85
      },
      "metadata": {
        "vendorId": "personalis",
        "vendorName": "Personalis",
        "payerName": "Medicare",
        "testName": "MRD Assay",
        "coverageType": "medicare",
        "effectiveDate": null,
        "changeType": "coverage_announcement",
        "deterministicMatches": [],
        "llmSuggestedTests": [
          "NeXT Personal",
          "ctDNA monitoring assay",
          "ctDNA test",
          "Personalis Assay"
        ]
      },
      "status": "ignored"
    },
    {
      "submissionId": "sub-2026-mlg093hsdweh",
      "source": "vendor",
      "type": "vendor_new_test",
      "title": "QIAGEN: Launches QIAsprint Connect High-Throughput Automation System",
      "summary": "High-throughput automation system for labs worldwide showcased at SLAS 2026",
      "url": "https://corporate.qiagen.com/newsroom/press-releases/default.aspx",
      "detectedAt": "2026-02-05T20:04:56.161Z",
      "triageHint": {
        "daemonScore": 8,
        "reason": "",
        "suggestedAction": "new_test",
        "suggestedTestName": "QIAsprint Connect High-Throughput Automation System",
        "confidence": 0.85
      },
      "metadata": {
        "vendorId": "qiagen",
        "vendorName": "QIAGEN",
        "testName": "QIAsprint Connect High-Throughput Automation System",
        "category": "hct",
        "description": "High-throughput automation system for labs worldwide showcased at SLAS 2026",
        "launchDate": null
      },
      "status": "ignored"
    },
    {
      "submissionId": "sub-2026-mlg093hsgqm3",
      "source": "payers",
      "type": "payer_policy_update",
      "title": "Blue Cross NC: Liquid Biopsy (AHS-G2054) Updated",
      "summary": "Blue Cross NC provides coverage for liquid biopsy/ctDNA testing in specific clinical scenarios for NSCLC, HR-positive/HER2-negative breast cancer, and castration-resistant prostate cancer when tissue testing is inadequate or for specific biomarker analysis. However, the policy considers liquid biopsy testing for cancer screening (including GRAIL Galleri) and monitoring of other malignancies as investigational and not covered.",
      "url": "https://www.bluecrossnc.com/providers/policies-guidelines-codes/commercial/laboratory/updates/liquid-biopsy",
      "detectedAt": "2026-02-05T20:09:37.497Z",
      "triageHint": {
        "daemonScore": 8,
        "reason": "",
        "suggestedAction": "coverage_update",
        "suggestedTestName": null,
        "confidence": 0.85
      },
      "metadata": {
        "payerId": "bcbsnc",
        "payerName": "Blue Cross NC",
        "policyId": "bcbsnc-liquid-biopsy-g2054",
        "policyName": "Liquid Biopsy (AHS-G2054)",
        "policyType": "liquid_biopsy",
        "contentType": "static_html",
        "testsFound": [
          "trm-1",
          "tds-23",
          "ecd-2",
          "mced"
        ],
        "isNewPolicy": true,
        "analysis": {
          "summary": "Blue Cross NC provides coverage for liquid biopsy/ctDNA testing in specific clinical scenarios for NSCLC, HR-positive/HER2-negative breast cancer, and castration-resistant prostate cancer when tissue testing is inadequate or for specific biomarker analysis. However, the policy considers liquid biopsy testing for cancer screening (including GRAIL Galleri) and monitoring of other malignancies as investigational and not covered.",
          "coverageStatus": "restricts",
          "keyConditions": [
            "NSCLC patients when tissue-based testing is infeasible or insufficient",
            "HR-positive/HER2-negative breast cancer patients for PIK3CA testing when considering targeted therapy",
            "Castration-resistant prostate cancer patients for AR-V2 and BRCA1/BRCA2 testing",
            "Annual testing permitted for qualifying patients",
            "Must be for specific biomarker analysis rather than general screening"
          ],
          "testsExplicitlyMentioned": [
            "GRAIL Galleri - considered investigational for screening"
          ],
          "significantChanges": [
            "Cannot determine changes as this appears to be a current policy document rather than an update showing before/after coverage positions"
          ],
          "confidence": 0.9
        },
        "extraction": {
          "stance": "denies",
          "stanceConfidence": 0.8,
          "cancerTypes": [
            "Breast",
            "NSCLC",
            "Prostate"
          ],
          "priorAuth": "unknown",
          "effectiveDate": "2019-04-01"
        },
        "change": {
          "priority": "high",
          "changedHashes": [
            "new_document"
          ],
          "summary": "[HIGH] Changed: New document"
        },
        "delegationDetected": false,
        "artifactId": {
          "artifactId": "bcbsnc_bcbsnc-liquid-biopsy-g2054_2026-02-05_97c8003af937",
          "artifactPath": "data/artifacts/bcbsnc/bcbsnc_bcbsnc-liquid-biopsy-g2054_2026-02-05_97c8003af937",
          "contentHash": "97c8003af937e8ca6c2a1068b0d3cd0843f785ac41d585f5254e2dccb316ffc5"
        },
        "pdfDiff": null
      },
      "status": "ignored"
    },
    {
      "submissionId": "sub-2026-mlg093hsr2sc",
      "source": "payers",
      "type": "payer_policy_update",
      "title": "BCBS Kansas: Circulating Tumor DNA and Circulating Tumor Cells for Cancer Management (Liquid Biopsy) Updated",
      "summary": "Unable to analyze coverage position due to corrupted document content. The provided content appears to be PDF encoding data rather than readable policy text, making it impossible to determine BCBS Kansas's coverage stance on ctDNA, liquid biopsy, and MRD testing.",
      "url": "https://www.bcbsks.com/medical-policies/circulating-tumor-dna-and-circulating-tumor-cells-cancer-management-liquid-biopsy",
      "detectedAt": "2026-02-05T20:09:37.498Z",
      "triageHint": {
        "daemonScore": 3,
        "reason": "",
        "suggestedAction": "coverage_update",
        "suggestedTestName": null,
        "confidence": 0.35
      },
      "metadata": {
        "payerId": "bcbsks",
        "payerName": "BCBS Kansas",
        "policyId": "bcbsks-ctdna-liquid-biopsy",
        "policyName": "Circulating Tumor DNA and Circulating Tumor Cells for Cancer Management (Liquid Biopsy)",
        "policyType": "liquid_biopsy",
        "contentType": "static_html",
        "testsFound": [],
        "isNewPolicy": true,
        "analysis": {
          "summary": "Unable to analyze coverage position due to corrupted document content. The provided content appears to be PDF encoding data rather than readable policy text, making it impossible to determine BCBS Kansas's coverage stance on ctDNA, liquid biopsy, and MRD testing.",
          "coverageStatus": "unclear",
          "keyConditions": [],
          "testsExplicitlyMentioned": [],
          "significantChanges": [],
          "confidence": 0
        },
        "extraction": {
          "stance": "unclear",
          "stanceConfidence": 0.3,
          "cancerTypes": [],
          "priorAuth": "unknown",
          "effectiveDate": null
        },
        "change": {
          "priority": "high",
          "changedHashes": [
            "new_document"
          ],
          "summary": "[HIGH] Changed: New document"
        },
        "delegationDetected": false,
        "artifactId": {
          "artifactId": "bcbsks_bcbsks-ctdna-liquid-biopsy_2026-02-05_4d2d029a439f",
          "artifactPath": "data/artifacts/bcbsks/bcbsks_bcbsks-ctdna-liquid-biopsy_2026-02-05_4d2d029a439f",
          "contentHash": "4d2d029a439fb6b0521261aac41f67a5c4186a6c4e9b9a76a926d6399e69fcc4"
        },
        "pdfDiff": null
      },
      "status": "ignored"
    },
    {
      "submissionId": "sub-2026-mlg093hsi2ly",
      "source": "payers",
      "type": "payer_policy_update",
      "title": "BCBS Rhode Island: Circulating Tumor DNA and Circulating Tumor Cells for Cancer Management (Liquid Biopsy) Updated",
      "summary": "BCBS Rhode Island denies coverage for circulating tumor DNA and circulating tumor cell testing for all indications, stating the evidence is insufficient to determine effects on health outcomes. The policy considers these tests not medically necessary for commercial products and not covered for Medicare Advantage plans.",
      "url": "https://www.bcbsri.com/providers/sites/providers/files/policies/2026/01/2026%20Circulating%20Tumor%20DNA%20and%20Circulating%20Tumor%20Cells%20for%20Cancer%20Management%20(Liquid%20Biopsy)_0.pdf",
      "detectedAt": "2026-02-05T20:09:37.499Z",
      "triageHint": {
        "daemonScore": 8,
        "reason": "",
        "suggestedAction": "coverage_update",
        "suggestedTestName": null,
        "confidence": 0.85
      },
      "metadata": {
        "payerId": "bcbsri",
        "payerName": "BCBS Rhode Island",
        "policyId": "bcbsri-ctdna-2026",
        "policyName": "Circulating Tumor DNA and Circulating Tumor Cells for Cancer Management (Liquid Biopsy)",
        "policyType": "liquid_biopsy",
        "contentType": "pdf",
        "testsFound": [],
        "isNewPolicy": true,
        "analysis": {
          "summary": "BCBS Rhode Island denies coverage for circulating tumor DNA and circulating tumor cell testing for all indications, stating the evidence is insufficient to determine effects on health outcomes. The policy considers these tests not medically necessary for commercial products and not covered for Medicare Advantage plans.",
          "coverageStatus": "denies",
          "keyConditions": [
            "Not covered for all indications",
            "Evidence insufficient to determine effects on health outcomes",
            "Not medically necessary for commercial products",
            "Not covered for Medicare Advantage plans",
            "Clinical validity and clinical utility data lacking"
          ],
          "testsExplicitlyMentioned": [
            "Circulating tumor DNA (ctDNA) testing - denied for all uses",
            "Circulating tumor cells (CTCs) testing - denied for all uses",
            "Liquid biopsy - denied for all indications"
          ],
          "significantChanges": [
            "Policy effective date 01/01/2024 with last review 01/07/2026",
            "Comprehensive denial across all cancer types and all liquid biopsy applications",
            "Exclusions noted for certain specific cancer types that are covered under separate policies"
          ],
          "confidence": 0.95
        },
        "extraction": {
          "stance": "denies",
          "stanceConfidence": 0.7,
          "cancerTypes": [
            "All"
          ],
          "priorAuth": "unknown",
          "effectiveDate": null
        },
        "change": {
          "priority": "high",
          "changedHashes": [
            "new_document"
          ],
          "summary": "[HIGH] Changed: New document"
        },
        "delegationDetected": false,
        "artifactId": {
          "artifactId": "bcbsri_bcbsri-ctdna-2026_2026-02-05_c8bef01960b3",
          "artifactPath": "data/artifacts/bcbsri/bcbsri_bcbsri-ctdna-2026_2026-02-05_c8bef01960b3",
          "contentHash": "c8bef01960b3e3bb1c78b5e11c11c3885ebf5f6dfae3a7d3d8d9faa49ffeb873"
        },
        "pdfDiff": {
          "summary": "New document: 1 PLA codes, 2 CPT codes, 1 named tests.",
          "addedCodes": {
            "pla": [
              "0091U"
            ],
            "cpt": [
              "86152",
              "86153"
            ],
            "hcpcs": [
              "S0500"
            ]
          },
          "removedCodes": {
            "pla": [],
            "cpt": [],
            "hcpcs": []
          }
        }
      },
      "status": "ignored"
    },
    {
      "submissionId": "sub-2026-mlg093hs7f3b",
      "source": "payers",
      "type": "payer_policy_update",
      "title": "Florida Blue: Tumor/Genetic Markers (MCG 05-86000-22) Updated",
      "summary": "Unable to analyze coverage position as the document content could not be retrieved due to a technical error.",
      "url": "https://mcgs.bcbsfl.com/MCG?mcgId=05-86000-22",
      "detectedAt": "2026-02-05T20:09:37.500Z",
      "triageHint": {
        "daemonScore": 3,
        "reason": "",
        "suggestedAction": "coverage_update",
        "suggestedTestName": null,
        "confidence": 0.35
      },
      "metadata": {
        "payerId": "floridablue",
        "payerName": "Florida Blue",
        "policyId": "floridablue-tumor-markers",
        "policyName": "Tumor/Genetic Markers (MCG 05-86000-22)",
        "policyType": "tumor_markers",
        "contentType": "html",
        "testsFound": [],
        "isNewPolicy": true,
        "analysis": {
          "summary": "Unable to analyze coverage position as the document content could not be retrieved due to a technical error.",
          "coverageStatus": "unclear",
          "keyConditions": [],
          "testsExplicitlyMentioned": [],
          "significantChanges": [],
          "confidence": 0
        },
        "extraction": {
          "stance": "unclear",
          "stanceConfidence": 0.3,
          "cancerTypes": [],
          "priorAuth": "unknown",
          "effectiveDate": null
        },
        "change": {
          "priority": "high",
          "changedHashes": [
            "new_document"
          ],
          "summary": "[HIGH] Changed: New document"
        },
        "delegationDetected": false,
        "artifactId": {
          "artifactId": "floridablue_floridablue-tumor-markers_2026-02-05_d79b60506700",
          "artifactPath": "data/artifacts/floridablue/floridablue_floridablue-tumor-markers_2026-02-05_d79b60506700",
          "contentHash": "d79b6050670073cf291a28a2c1b6aa7ab8e810b8e350a41ce355075622e19774"
        },
        "pdfDiff": null
      },
      "status": "ignored"
    },
    {
      "submissionId": "sub-2026-mlg093hsyl4o",
      "source": "payers",
      "type": "payer_policy_update",
      "title": "Wellmark BCBS (Iowa/South Dakota): Circulating Tumor DNA and Circulating Tumor Cells for Cancer Management (Liquid Biopsies) Updated",
      "summary": "Unable to analyze coverage position as the document content shows a 403 CloudFront error and does not contain the actual insurance policy text.",
      "url": "https://www.wellmark.com/Provider/MedPoliciesAndAuthorizations/MedicalPolicies/policies/Detection_Quantification.aspx",
      "detectedAt": "2026-02-05T20:09:37.501Z",
      "triageHint": {
        "daemonScore": 3,
        "reason": "",
        "suggestedAction": "coverage_update",
        "suggestedTestName": null,
        "confidence": 0.35
      },
      "metadata": {
        "payerId": "wellmark",
        "payerName": "Wellmark BCBS (Iowa/South Dakota)",
        "policyId": "wellmark-ctdna-liquid-biopsy",
        "policyName": "Circulating Tumor DNA and Circulating Tumor Cells for Cancer Management (Liquid Biopsies)",
        "policyType": "liquid_biopsy",
        "contentType": "html",
        "testsFound": [],
        "isNewPolicy": true,
        "analysis": {
          "summary": "Unable to analyze coverage position as the document content shows a 403 CloudFront error and does not contain the actual insurance policy text.",
          "coverageStatus": "unclear",
          "keyConditions": [],
          "testsExplicitlyMentioned": [],
          "significantChanges": [],
          "confidence": 0
        },
        "extraction": {
          "stance": "unclear",
          "stanceConfidence": 0.3,
          "cancerTypes": [],
          "priorAuth": "unknown",
          "effectiveDate": null
        },
        "change": {
          "priority": "high",
          "changedHashes": [
            "new_document"
          ],
          "summary": "[HIGH] Changed: New document"
        },
        "delegationDetected": false,
        "artifactId": {
          "artifactId": "wellmark_wellmark-ctdna-liquid-biopsy_2026-02-05_05a0e144f1a6",
          "artifactPath": "data/artifacts/wellmark/wellmark_wellmark-ctdna-liquid-biopsy_2026-02-05_05a0e144f1a6",
          "contentHash": "05a0e144f1a6bbbd9feecd956963e8b16846e66eecbd7c92d111b7e138f34e0d"
        },
        "pdfDiff": null
      },
      "status": "ignored"
    },
    {
      "submissionId": "sub-2026-mlg093hsgdbh",
      "source": "payers",
      "type": "payer_policy_update",
      "title": "Regence BCBS (OR/WA/UT/ID): Circulating Tumor DNA and Circulating Tumor Cells (LAB46) Updated",
      "summary": "Regence BCBS restricts ctDNA/liquid biopsy coverage to very limited targeted treatment selection scenarios (advanced ER+/HER2- breast cancer or when tissue testing is impossible) but explicitly denies coverage for MRD testing and multi-cancer screening. All other ctDNA applications including Signatera, Galleri, and Guardant360 for MRD/screening purposes are considered investigational.",
      "url": "http://blue.regence.com/trgmedpol/lab/lab46.pdf",
      "detectedAt": "2026-02-05T20:09:37.502Z",
      "triageHint": {
        "daemonScore": 8,
        "reason": "",
        "suggestedAction": "coverage_update",
        "suggestedTestName": null,
        "confidence": 0.85
      },
      "metadata": {
        "payerId": "regence",
        "payerName": "Regence BCBS (OR/WA/UT/ID)",
        "policyId": "regence-lab46",
        "policyName": "Circulating Tumor DNA and Circulating Tumor Cells (LAB46)",
        "policyType": "liquid_biopsy",
        "contentType": "pdf",
        "testsFound": [
          "mrd-7",
          "tds-6",
          "trm-1",
          "ecd-2",
          "mced"
        ],
        "isNewPolicy": true,
        "analysis": {
          "summary": "Regence BCBS restricts ctDNA/liquid biopsy coverage to very limited targeted treatment selection scenarios (advanced ER+/HER2- breast cancer or when tissue testing is impossible) but explicitly denies coverage for MRD testing and multi-cancer screening. All other ctDNA applications including Signatera, Galleri, and Guardant360 for MRD/screening purposes are considered investigational.",
          "coverageStatus": "restricts",
          "keyConditions": [
            "Advanced/metastatic ER-positive, HER2-negative breast cancer",
            "Tissue-based testing cannot be performed (insufficient sample or inaccessible tumor)",
            "Test must include genes with FDA-approved targeted therapy for the specific cancer indication",
            "Limited to targeted treatment selection only"
          ],
          "testsExplicitlyMentioned": [
            "Guardant360 CDx - covered for limited targeted treatment selection only",
            "Signatera - explicitly listed as investigational MRD test (not covered)",
            "Galleri - explicitly listed as investigational screening test (not covered)"
          ],
          "significantChanges": [
            "Policy effective January 1, 2026 suggests this is a new or updated policy",
            "Comprehensive lists of covered vs investigational tests indicates recent policy restructuring",
            "Specific exclusion of MRD testing with named tests represents clear policy restriction"
          ],
          "confidence": 0.95
        },
        "extraction": {
          "stance": "denies",
          "stanceConfidence": 0.8,
          "cancerTypes": [
            "All",
            "Breast",
            "Solid tumor"
          ],
          "priorAuth": "unknown",
          "effectiveDate": "2026-01-01"
        },
        "change": {
          "priority": "high",
          "changedHashes": [
            "new_document"
          ],
          "summary": "[HIGH] Changed: New document"
        },
        "delegationDetected": false,
        "artifactId": {
          "artifactId": "regence_regence-lab46_2026-02-05_f122c3a56cb1",
          "artifactPath": "data/artifacts/regence/regence_regence-lab46_2026-02-05_f122c3a56cb1",
          "contentHash": "f122c3a56cb1d78f8fc9b2a76caa64e8a86f94c88b48dcf30a08b3caa23e74a0"
        },
        "pdfDiff": {
          "summary": "New document: 36 PLA codes, 5 CPT codes, 16 named tests.",
          "addedCodes": {
            "pla": [
              "0091U",
              "0179U",
              "0229U",
              "0239U",
              "0242U",
              "0285U",
              "0306U",
              "0307U",
              "0317U",
              "0326U",
              "0333U",
              "0338U",
              "0340U",
              "0388U",
              "0405U",
              "0409U",
              "0410U",
              "0422U",
              "0485U",
              "0486U",
              "0487U",
              "0490U",
              "0491U",
              "0492U",
              "0507U",
              "0530U",
              "0539U",
              "0560U",
              "0561U",
              "0562U",
              "0565U",
              "0569U",
              "0571U",
              "0585U",
              "0611U",
              "0612U"
            ],
            "cpt": [
              "81462",
              "81463",
              "81464",
              "86152",
              "86153"
            ],
            "hcpcs": [
              "S0500"
            ]
          },
          "removedCodes": {
            "pla": [],
            "cpt": [],
            "hcpcs": []
          }
        }
      },
      "status": "ignored"
    },
    {
      "submissionId": "sub-2026-mlg093hsmzvl",
      "source": "payers",
      "type": "payer_policy_update",
      "title": "Centene (Superior, Ambetter, etc.): Oncology Circulating Tumor DNA and Circulating Tumor Cells (CP.MP.239) Updated",
      "summary": "Centene provides limited coverage for ctDNA/liquid biopsy testing, primarily supporting comprehensive and lung-focused panels for advanced/metastatic lung cancers and select other cancers when tissue biopsy is not feasible. The policy denies coverage for colorectal and melanoma-focused panels and restricts simultaneous testing with tissue-based approaches.",
      "url": "https://www.superiorhealthplan.com/content/dam/centene/Superior/policies/clinical-policies/CP.MP.239.pdf",
      "detectedAt": "2026-02-05T20:09:37.503Z",
      "triageHint": {
        "daemonScore": 8,
        "reason": "",
        "suggestedAction": "coverage_update",
        "suggestedTestName": null,
        "confidence": 0.85
      },
      "metadata": {
        "payerId": "centene",
        "payerName": "Centene (Superior, Ambetter, etc.)",
        "policyId": "centene-ctdna-mp239",
        "policyName": "Oncology Circulating Tumor DNA and Circulating Tumor Cells (CP.MP.239)",
        "policyType": "liquid_biopsy",
        "contentType": "pdf",
        "testsFound": [
          "trm-1",
          "ecd-7"
        ],
        "isNewPolicy": true,
        "analysis": {
          "summary": "Centene provides limited coverage for ctDNA/liquid biopsy testing, primarily supporting comprehensive and lung-focused panels for advanced/metastatic lung cancers and select other cancers when tissue biopsy is not feasible. The policy denies coverage for colorectal and melanoma-focused panels and restricts simultaneous testing with tissue-based approaches.",
          "coverageStatus": "restricts",
          "keyConditions": [
            "Advanced (stage IIIb or higher) or metastatic lung cancers (adenocarcinoma, large cell, squamous cell, NSCLC NOS)",
            "Locally advanced/metastatic pancreatic adenocarcinoma, gastric cancer, esophageal/esophagogastric junction cancer, metastatic prostate cancer",
            "Patient must be candidate for anti-cancer therapy",
            "Patient must be medically unfit for invasive tissue sampling OR not have biopsy-amenable lesion",
            "Testing cannot be performed simultaneously with or subsequent to solid tumor tissue testing"
          ],
          "testsExplicitlyMentioned": [
            "Guardant360 CDx (0242U) - covered for comprehensive profiling under specific conditions",
            "Guardant360 LDT (81455) - covered for comprehensive profiling under specific conditions",
            "FoundationOne Liquid CDx (0239U) - covered for comprehensive profiling under specific conditions"
          ],
          "significantChanges": [
            "Cannot determine specific changes as this appears to be a static policy document rather than an update"
          ],
          "confidence": 0.9
        },
        "extraction": {
          "stance": "denies",
          "stanceConfidence": 0.5999999999999999,
          "cancerTypes": [
            "All",
            "CRC",
            "Lung",
            "Melanoma",
            "NSCLC",
            "Prostate",
            "Solid tumor"
          ],
          "priorAuth": "unknown",
          "effectiveDate": null
        },
        "change": {
          "priority": "high",
          "changedHashes": [
            "new_document"
          ],
          "summary": "[HIGH] Changed: New document"
        },
        "delegationDetected": false,
        "artifactId": {
          "artifactId": "centene_centene-ctdna-mp239_2026-02-05_d62dba99c014",
          "artifactPath": "data/artifacts/centene/centene_centene-ctdna-mp239_2026-02-05_d62dba99c014",
          "contentHash": "d62dba99c014fdb93b72a9fb1cce402973e2c5f4768979e88d0508c8e58eed59"
        },
        "pdfDiff": {
          "summary": "New document: 4 PLA codes, 11 CPT codes, 4 named tests.",
          "addedCodes": {
            "pla": [
              "0177U",
              "0179U",
              "0239U",
              "0242U"
            ],
            "cpt": [
              "81210",
              "81235",
              "81275",
              "81276",
              "81309",
              "81311",
              "81445",
              "81455",
              "81479",
              "86152",
              "86153"
            ],
            "hcpcs": [
              "S3711"
            ]
          },
          "removedCodes": {
            "pla": [],
            "cpt": [],
            "hcpcs": []
          }
        }
      },
      "status": "ignored"
    },
    {
      "submissionId": "sub-2026-mlg093hsrueg",
      "source": "payers",
      "type": "payer_policy_update",
      "title": "TRICARE (Defense Health Agency): Genetic Testing and Counseling (TPM Chapter 6, Section 3.1) Updated",
      "summary": "Unable to analyze coverage position as the document content is not available (404 error). The TRICARE policy document for Genetic Testing and Counseling could not be accessed.",
      "url": "https://manuals.health.mil/pages/DisplayManualHtmlFile/TP15/48/AsOf/TP15/C6S3_1.html",
      "detectedAt": "2026-02-05T20:09:37.504Z",
      "triageHint": {
        "daemonScore": 3,
        "reason": "",
        "suggestedAction": "coverage_update",
        "suggestedTestName": null,
        "confidence": 0.35
      },
      "metadata": {
        "payerId": "tricare",
        "payerName": "TRICARE (Defense Health Agency)",
        "policyId": "tricare-genetic-testing",
        "policyName": "Genetic Testing and Counseling (TPM Chapter 6, Section 3.1)",
        "policyType": "molecular_oncology",
        "contentType": "html",
        "testsFound": [],
        "isNewPolicy": true,
        "analysis": {
          "summary": "Unable to analyze coverage position as the document content is not available (404 error). The TRICARE policy document for Genetic Testing and Counseling could not be accessed.",
          "coverageStatus": "unclear",
          "keyConditions": [],
          "testsExplicitlyMentioned": [],
          "significantChanges": [],
          "confidence": 0
        },
        "extraction": {
          "stance": "unclear",
          "stanceConfidence": 0.3,
          "cancerTypes": [],
          "priorAuth": "unknown",
          "effectiveDate": null
        },
        "change": {
          "priority": "high",
          "changedHashes": [
            "new_document"
          ],
          "summary": "[HIGH] Changed: New document"
        },
        "delegationDetected": false,
        "artifactId": {
          "artifactId": "tricare_tricare-genetic-testing_2026-02-05_3578b0673866",
          "artifactPath": "data/artifacts/tricare/tricare_tricare-genetic-testing_2026-02-05_3578b0673866",
          "contentHash": "3578b0673866622ad3a64835bf04e0106fda84f533e7bbcc95955b759f7e0fb4"
        },
        "pdfDiff": null
      },
      "status": "ignored"
    },
    {
      "submissionId": "sub-2026-mlg093hsdi4z",
      "source": "payers",
      "type": "payer_policy_update",
      "title": "HCSC (IL, MT, NM, OK, TX): Circulating Tumor DNA (Liquid Biopsy) Updated",
      "summary": "The provided content appears to be only the general disclaimer and terms of use page from HCSC's medical policy website, not the actual medical policy content for circulating tumor DNA/liquid biopsy coverage. No specific coverage position can be determined from this introductory material.",
      "url": "https://medicalpolicy.hcsc.com/home.html?corpEntCd=HCSC",
      "detectedAt": "2026-02-05T20:09:37.505Z",
      "triageHint": {
        "daemonScore": 3,
        "reason": "",
        "suggestedAction": "coverage_update",
        "suggestedTestName": null,
        "confidence": 0.35
      },
      "metadata": {
        "payerId": "hcsc",
        "payerName": "HCSC (IL, MT, NM, OK, TX)",
        "policyId": "hcsc-liquid-biopsy",
        "policyName": "Circulating Tumor DNA (Liquid Biopsy)",
        "policyType": "liquid_biopsy",
        "contentType": "html",
        "testsFound": [],
        "isNewPolicy": true,
        "analysis": {
          "summary": "The provided content appears to be only the general disclaimer and terms of use page from HCSC's medical policy website, not the actual medical policy content for circulating tumor DNA/liquid biopsy coverage. No specific coverage position can be determined from this introductory material.",
          "coverageStatus": "unclear",
          "keyConditions": [],
          "testsExplicitlyMentioned": [],
          "significantChanges": [],
          "confidence": 0.1
        },
        "extraction": {
          "stance": "restricts",
          "stanceConfidence": 0.7,
          "cancerTypes": [],
          "priorAuth": "unknown",
          "effectiveDate": null
        },
        "change": {
          "priority": "high",
          "changedHashes": [
            "new_document"
          ],
          "summary": "[HIGH] Changed: New document"
        },
        "delegationDetected": false,
        "artifactId": {
          "artifactId": "hcsc_hcsc-liquid-biopsy_2026-02-05_7d91163b11a3",
          "artifactPath": "data/artifacts/hcsc/hcsc_hcsc-liquid-biopsy_2026-02-05_7d91163b11a3",
          "contentHash": "7d91163b11a3a2b7a6aae2435dc446567e93ca5418058956802d01efd5c84ab5"
        },
        "pdfDiff": null
      },
      "status": "ignored"
    },
    {
      "submissionId": "sub-2026-mlg093hsdu1t",
      "source": "payers",
      "type": "payer_policy_update",
      "title": "BCBS Alabama: Medical Policies Portal Updated",
      "summary": "This appears to be a navigation portal page for BCBS Alabama's medical policies rather than a specific policy document. No specific coverage position for ctDNA/liquid biopsy tests can be determined from this content.",
      "url": "https://al-policies.exploremyplan.com/portal/web/al-policies/home/-/categories/150513503",
      "detectedAt": "2026-02-05T20:09:37.506Z",
      "triageHint": {
        "daemonScore": 3,
        "reason": "",
        "suggestedAction": "coverage_update",
        "suggestedTestName": null,
        "confidence": 0.35
      },
      "metadata": {
        "payerId": "bcbsal",
        "payerName": "BCBS Alabama",
        "policyId": "bcbsal-policy-portal",
        "policyName": "Medical Policies Portal",
        "policyType": "molecular_oncology",
        "contentType": "html",
        "testsFound": [],
        "isNewPolicy": true,
        "analysis": {
          "summary": "This appears to be a navigation portal page for BCBS Alabama's medical policies rather than a specific policy document. No specific coverage position for ctDNA/liquid biopsy tests can be determined from this content.",
          "coverageStatus": "unclear",
          "keyConditions": [
            "Technology must have final regulatory approval",
            "Scientific evidence must permit conclusions on health outcomes",
            "Technology must improve net health outcome",
            "Must be as beneficial as established alternatives",
            "Improvement must be attainable outside investigational setting"
          ],
          "testsExplicitlyMentioned": [],
          "significantChanges": [],
          "confidence": 0.1
        },
        "extraction": {
          "stance": "denies",
          "stanceConfidence": 0.5999999999999999,
          "cancerTypes": [],
          "priorAuth": "unknown",
          "effectiveDate": null
        },
        "change": {
          "priority": "high",
          "changedHashes": [
            "new_document"
          ],
          "summary": "[HIGH] Changed: New document"
        },
        "delegationDetected": false,
        "artifactId": {
          "artifactId": "bcbsal_bcbsal-policy-portal_2026-02-05_6ba24c99de32",
          "artifactPath": "data/artifacts/bcbsal/bcbsal_bcbsal-policy-portal_2026-02-05_6ba24c99de32",
          "contentHash": "6ba24c99de325963ffb72ed6edde6644f376aa52d2fc270946332d5ba502ba63"
        },
        "pdfDiff": null
      },
      "status": "ignored"
    },
    {
      "submissionId": "sub-2026-mlg093hsp6q9",
      "source": "payers",
      "type": "payer_policy_update",
      "title": "Anthem/Elevance Health: Molecular Profiling for Solid Tumors (CG-GENE-13) Updated",
      "summary": "This policy document (CG-GENE-13) focuses on genetic testing for inherited diseases and explicitly excludes ctDNA and liquid biopsy testing by referring to separate policy GENE.00049. The document does not provide coverage decisions for ctDNA, liquid biopsy, or MRD testing as these are outside its scope.",
      "url": "https://files.providernews.anthem.com/2002/CG-GENE-13.pdf",
      "detectedAt": "2026-02-05T20:09:43.315Z",
      "triageHint": {
        "daemonScore": 3,
        "reason": "",
        "suggestedAction": "coverage_update",
        "suggestedTestName": null,
        "confidence": 0.35
      },
      "metadata": {
        "payerId": "anthem",
        "payerName": "Anthem/Elevance Health",
        "policyId": "anthem-gene-13",
        "policyName": "Molecular Profiling for Solid Tumors (CG-GENE-13)",
        "policyType": "molecular_oncology",
        "docType": "medical_policy",
        "contentType": "pdf",
        "testsFound": [],
        "isNewPolicy": true,
        "analysis": {
          "summary": "This policy document (CG-GENE-13) focuses on genetic testing for inherited diseases and explicitly excludes ctDNA and liquid biopsy testing by referring to separate policy GENE.00049. The document does not provide coverage decisions for ctDNA, liquid biopsy, or MRD testing as these are outside its scope.",
          "coverageStatus": "unclear",
          "keyConditions": [
            "Document explicitly excludes liquid biopsy testing - refers to GENE.00049",
            "Policy scope limited to germline genetic testing for inherited diseases",
            "Requires genetic counseling for covered genetic tests",
            "Tests must have established clinical utility and impact management decisions"
          ],
          "testsExplicitlyMentioned": [],
          "significantChanges": [
            "Document was revised on 12/28/2022 with last review 11/10/2022",
            "Explicit exclusion statement refers to separate liquid biopsy policy GENE.00049"
          ],
          "confidence": 0.95
        },
        "extraction": {
          "stance": "denies",
          "stanceConfidence": 0.7,
          "cancerTypes": [
            "All"
          ],
          "priorAuth": "unknown",
          "effectiveDate": null
        },
        "change": {
          "priority": "high",
          "changedHashes": [
            "new_document"
          ],
          "summary": "[HIGH] Changed: New document"
        },
        "delegationDetected": false,
        "artifactId": {
          "artifactId": "anthem_anthem-gene-13_2026-02-05_03e99b153c66",
          "artifactPath": "data/artifacts/anthem/anthem_anthem-gene-13_2026-02-05_03e99b153c66",
          "contentHash": "03e99b153c666e1bfe33288c5acdbfc9a3573995ab85ea7c800b4a02135e6784"
        },
        "pdfDiff": {
          "summary": "New document: 11 PLA codes, 106 CPT codes, 1 named tests.",
          "addedCodes": {
            "pla": [
              "0012U",
              "0094U",
              "0170U",
              "0218U",
              "0230U",
              "0231U",
              "0232U",
              "0233U",
              "0234U",
              "0236U",
              "0355U"
            ],
            "cpt": [
              "81161",
              "81171",
              "81172",
              "81173",
              "81174",
              "81177",
              "81178",
              "81179",
              "81180",
              "81181",
              "81182",
              "81183",
              "81184",
              "81185",
              "81186",
              "81187",
              "81188",
              "81189",
              "81190",
              "81200",
              "81204",
              "81205",
              "81209",
              "81220",
              "81221",
              "81222",
              "81223",
              "81224",
              "81234",
              "81239",
              "81240",
              "81241",
              "81242",
              "81243",
              "81244",
              "81250",
              "81251",
              "81252",
              "81253",
              "81254",
              "81255",
              "81256",
              "81257",
              "81258",
              "81259",
              "81260",
              "81269",
              "81271",
              "81274",
              "81284",
              "81285",
              "81286",
              "81289",
              "81290",
              "81291",
              "81302",
              "81303",
              "81304",
              "81309",
              "81312",
              "81324",
              "81325",
              "81326",
              "81328",
              "81329",
              "81330",
              "81331",
              "81332",
              "81333",
              "81336",
              "81337",
              "81343",
              "81344",
              "81361",
              "81362",
              "81363",
              "81364",
              "81400",
              "81401",
              "81402",
              "81403",
              "81404",
              "81405",
              "81406",
              "81407",
              "81408",
              "81410",
              "81411",
              "81414",
              "81415",
              "81416",
              "81417",
              "81425",
              "81427",
              "81430",
              "81431",
              "81440",
              "81442",
              "81443",
              "81460",
              "81465",
              "81470",
              "81471",
              "81479",
              "81506",
              "81599"
            ],
            "hcpcs": [
              "S1547",
              "S3800",
              "S3841",
              "S3842",
              "S3844",
              "S3845",
              "S3846",
              "S3849",
              "S3850",
              "S3852",
              "S3853",
              "S3861",
              "S3865",
              "S3866"
            ]
          },
          "removedCodes": {
            "pla": [],
            "cpt": [],
            "hcpcs": []
          }
        }
      },
      "status": "ignored"
    },
    {
      "submissionId": "sub-2026-mlg093hsz3m3",
      "source": "payers",
      "type": "payer_policy_update",
      "title": "Anthem/Elevance Health: Molecular Profiling Policy (GENE.00052) Updated",
      "summary": "Anthem/Elevance Health provides limited coverage for ctDNA panel testing only for specific scenarios: prostate cancer patients who are PARP inhibitor candidates when tissue is unavailable, advanced NSCLC patients for first-line therapy when tissue is inadequate, and FDA-approved companion diagnostic devices. All other uses of liquid biopsy appear to be denied.",
      "url": "https://files.providernews.anthem.com/2354/GENE.00052_Pub-05-25-2023.pdf",
      "detectedAt": "2026-02-05T20:09:43.316Z",
      "triageHint": {
        "daemonScore": 8,
        "reason": "",
        "suggestedAction": "coverage_update",
        "suggestedTestName": null,
        "confidence": 0.85
      },
      "metadata": {
        "payerId": "anthem",
        "payerName": "Anthem/Elevance Health",
        "policyId": "anthem-gene-52",
        "policyName": "Molecular Profiling Policy (GENE.00052)",
        "policyType": "molecular_oncology",
        "docType": "medical_policy",
        "contentType": "pdf",
        "testsFound": [
          "mrd-6",
          "mrd-14",
          "trm-1",
          "tds-1",
          "ecd-7",
          "ecd-2",
          "mced"
        ],
        "isNewPolicy": true,
        "analysis": {
          "summary": "Anthem/Elevance Health provides limited coverage for ctDNA panel testing only for specific scenarios: prostate cancer patients who are PARP inhibitor candidates when tissue is unavailable, advanced NSCLC patients for first-line therapy when tissue is inadequate, and FDA-approved companion diagnostic devices. All other uses of liquid biopsy appear to be denied.",
          "coverageStatus": "restricts",
          "keyConditions": [
            "FFPET tissue must be inadequate in quality/quantity or unavailable for testing",
            "Prostate cancer patients must be candidates for PARP inhibitor treatment",
            "NSCLC testing only prior to first-line therapy with specific gene panel requirements",
            "Tests must be FDA-approved companion diagnostic devices when applicable",
            "Specific minimum gene requirements for covered panels (ALK, BRAF, EGFR, ERBB2, KRAS, MET, NTRK, RET, ROS1 for NSCLC)"
          ],
          "testsExplicitlyMentioned": [
            "guardant-reveal",
            "navdx",
            "guardant360",
            "foundationone-liquid",
            "ctdx",
            "galleri",
            "mced"
          ],
          "significantChanges": [
            "Document appears to be a revision from 2023 but no specific previous version changes are detailed in the provided content",
            "Policy explicitly excludes early cancer detection/screening uses of liquid biopsy",
            "Policy explicitly excludes cancer surveillance applications"
          ],
          "confidence": 0.85
        },
        "extraction": {
          "stance": "denies",
          "stanceConfidence": 0.8,
          "cancerTypes": [
            "All",
            "Breast",
            "CRC"
          ],
          "priorAuth": "unknown",
          "effectiveDate": "2018-03-16"
        },
        "change": {
          "priority": "high",
          "changedHashes": [
            "new_document"
          ],
          "summary": "[HIGH] Changed: New document"
        },
        "delegationDetected": false,
        "artifactId": {
          "artifactId": "anthem_anthem-gene-52_2026-02-05_3aae824a0055",
          "artifactPath": "data/artifacts/anthem/anthem_anthem-gene-52_2026-02-05_3aae824a0055",
          "contentHash": "3aae824a00550b54c35937fe8f1ef3fa6adafb9cabca56a24be931895ec9e2cc"
        },
        "pdfDiff": {
          "summary": "New document: 73 PLA codes, 39 CPT codes, 16 named tests.",
          "addedCodes": {
            "pla": [
              "0012U",
              "0013U",
              "0014U",
              "0022U",
              "0036U",
              "0037U",
              "0048U",
              "0050U",
              "0056U",
              "0094U",
              "0101U",
              "0102U",
              "0103U",
              "0129U",
              "0130U",
              "0131U",
              "0132U",
              "0134U",
              "0135U",
              "0171U",
              "0179U",
              "0205U",
              "0211U",
              "0212U",
              "0213U",
              "0214U",
              "0215U",
              "0216U",
              "0217U",
              "0237U",
              "0238U",
              "0239U",
              "0242U",
              "0244U",
              "0250U",
              "0260U",
              "0264U",
              "0265U",
              "0266U",
              "0267U",
              "0268U",
              "0269U",
              "0270U",
              "0271U",
              "0272U",
              "0273U",
              "0274U",
              "0276U",
              "0277U",
              "0278U",
              "0297U",
              "0298U",
              "0299U",
              "0300U",
              "0306U",
              "0307U",
              "0326U",
              "0329U",
              "0331U",
              "0332U",
              "0333U",
              "0334U",
              "0335U",
              "0336U",
              "0343U",
              "0356U",
              "0368U",
              "0379U",
              "0388U",
              "0391U",
              "0397U",
              "0400U",
              "0401U"
            ],
            "cpt": [
              "81410",
              "81411",
              "81412",
              "81413",
              "81415",
              "81416",
              "81417",
              "81419",
              "81425",
              "81426",
              "81427",
              "81430",
              "81431",
              "81432",
              "81433",
              "81434",
              "81435",
              "81436",
              "81437",
              "81438",
              "81439",
              "81440",
              "81441",
              "81442",
              "81443",
              "81445",
              "81448",
              "81449",
              "81450",
              "81451",
              "81455",
              "81456",
              "81460",
              "81465",
              "81470",
              "81471",
              "81479",
              "81506",
              "81599"
            ],
            "hcpcs": []
          },
          "removedCodes": {
            "pla": [],
            "cpt": [],
            "hcpcs": []
          }
        }
      },
      "status": "ignored"
    },
    {
      "submissionId": "sub-2026-mlg093hsicxe",
      "source": "payers",
      "type": "payer_policy_update",
      "title": "Anthem/Elevance Health: Circulating Tumor DNA Panel Testing (GENE.00049) Updated",
      "summary": "Unable to analyze coverage position as the document content appears to be empty or corrupted, showing only formatting characters without readable policy text.",
      "url": "https://files.providernews.anthem.com/2372/GENE.00049.pdf",
      "detectedAt": "2026-02-05T20:09:43.317Z",
      "triageHint": {
        "daemonScore": 3,
        "reason": "",
        "suggestedAction": "coverage_update",
        "suggestedTestName": null,
        "confidence": 0.35
      },
      "metadata": {
        "payerId": "anthem",
        "payerName": "Anthem/Elevance Health",
        "policyId": "anthem-gene-49",
        "policyName": "Circulating Tumor DNA Panel Testing (GENE.00049)",
        "policyType": "liquid_biopsy",
        "docType": "medical_policy",
        "contentType": "pdf",
        "testsFound": [],
        "isNewPolicy": true,
        "analysis": {
          "summary": "Unable to analyze coverage position as the document content appears to be empty or corrupted, showing only formatting characters without readable policy text.",
          "coverageStatus": "unclear",
          "keyConditions": [],
          "testsExplicitlyMentioned": [],
          "significantChanges": [],
          "confidence": 0
        },
        "extraction": {
          "stance": "unclear",
          "stanceConfidence": 0.3,
          "cancerTypes": [],
          "priorAuth": "unknown",
          "effectiveDate": null
        },
        "change": {
          "priority": "high",
          "changedHashes": [
            "new_document"
          ],
          "summary": "[HIGH] Changed: New document"
        },
        "delegationDetected": false,
        "artifactId": {
          "artifactId": "anthem_anthem-gene-49_2026-02-05_1374c0ecff9f",
          "artifactPath": "data/artifacts/anthem/anthem_anthem-gene-49_2026-02-05_1374c0ecff9f",
          "contentHash": "1374c0ecff9f5520ea4a144c5754ae434cfea5ca52ec9af6e9916f20bd9275ed"
        },
        "pdfDiff": {
          "summary": "New document: 0 PLA codes, 0 CPT codes, 0 named tests.",
          "addedCodes": {
            "pla": [],
            "cpt": [],
            "hcpcs": []
          },
          "removedCodes": {
            "pla": [],
            "cpt": [],
            "hcpcs": []
          }
        }
      },
      "status": "ignored"
    },
    {
      "submissionId": "sub-2026-mlg093hsddz5",
      "source": "payers",
      "type": "payer_policy_update",
      "title": "Anthem/Elevance Health: Detection of Circulating Tumor Cells (LAB.00015) Updated",
      "summary": "This policy specifically covers circulating tumor cells (CTCs) detection and explicitly excludes ctDNA/liquid biopsy testing, stating it is addressed in separate applicable guidelines. The policy denies coverage for CTC testing, deeming it investigational and not medically necessary across all cancer types.",
      "url": "https://anthem.com/dam/medpolicies/abc/active/policies/mp_pw_a049885.html",
      "detectedAt": "2026-02-05T20:09:43.319Z",
      "triageHint": {
        "daemonScore": 3,
        "reason": "",
        "suggestedAction": "coverage_update",
        "suggestedTestName": null,
        "confidence": 0.35
      },
      "metadata": {
        "payerId": "anthem",
        "payerName": "Anthem/Elevance Health",
        "policyId": "anthem-lab-00015",
        "policyName": "Detection of Circulating Tumor Cells (LAB.00015)",
        "policyType": "ctdna",
        "docType": "medical_policy",
        "contentType": "static_html",
        "testsFound": [],
        "isNewPolicy": true,
        "analysis": {
          "summary": "This policy specifically covers circulating tumor cells (CTCs) detection and explicitly excludes ctDNA/liquid biopsy testing, stating it is addressed in separate applicable guidelines. The policy denies coverage for CTC testing, deeming it investigational and not medically necessary across all cancer types.",
          "coverageStatus": "unclear",
          "keyConditions": [
            "Policy explicitly states it does not address ctDNA/liquid biopsy testing",
            "Refers to separate applicable guidelines for ctDNA coverage decisions",
            "CTC testing (different technology) is denied as investigational"
          ],
          "testsExplicitlyMentioned": [],
          "significantChanges": [
            "Cannot determine changes as this appears to be current policy without comparison to previous versions"
          ],
          "confidence": 0.9
        },
        "extraction": {
          "stance": "denies",
          "stanceConfidence": 0.8,
          "cancerTypes": [
            "All",
            "Melanoma",
            "Myeloma",
            "Solid tumor"
          ],
          "priorAuth": "unknown",
          "effectiveDate": null
        },
        "change": {
          "priority": "high",
          "changedHashes": [
            "new_document"
          ],
          "summary": "[HIGH] Changed: New document"
        },
        "delegationDetected": false,
        "artifactId": {
          "artifactId": "anthem_anthem-lab-00015_2026-02-05_185474c0c32a",
          "artifactPath": "data/artifacts/anthem/anthem_anthem-lab-00015_2026-02-05_185474c0c32a",
          "contentHash": "185474c0c32aafe1fe1841ef9e0f507abf4c07adb81b0e451c1590600981e463"
        },
        "pdfDiff": null
      },
      "status": "ignored"
    },
    {
      "submissionId": "sub-2026-mlg093hsa7sb",
      "source": "payers",
      "type": "payer_policy_update",
      "title": "Anthem/Elevance Health: Hybrid Personalized MRD Tests (GENE.00059) Updated",
      "summary": "Anthem/Elevance Health considers hybrid personalized molecular residual disease (MRD) tests including Signatera and RaDaR to be investigational and not medically necessary for all indications. The policy cites lack of randomized controlled trials comparing health outcomes with versus without hybrid personalized MRD testing.",
      "url": "https://files.providernews.anthem.com/1781/GENE.00059.pdf",
      "detectedAt": "2026-02-05T20:09:43.320Z",
      "triageHint": {
        "daemonScore": 8,
        "reason": "",
        "suggestedAction": "coverage_update",
        "suggestedTestName": null,
        "confidence": 0.85
      },
      "metadata": {
        "payerId": "anthem",
        "payerName": "Anthem/Elevance Health",
        "policyId": "anthem-gene-59",
        "policyName": "Hybrid Personalized MRD Tests (GENE.00059)",
        "policyType": "mrd",
        "docType": "medical_policy",
        "contentType": "pdf",
        "testsFound": [
          "mrd-7",
          "trm-5"
        ],
        "isNewPolicy": true,
        "analysis": {
          "summary": "Anthem/Elevance Health considers hybrid personalized molecular residual disease (MRD) tests including Signatera and RaDaR to be investigational and not medically necessary for all indications. The policy cites lack of randomized controlled trials comparing health outcomes with versus without hybrid personalized MRD testing.",
          "coverageStatus": "denies",
          "keyConditions": [
            "No coverage for hybrid personalized MRD tests for any indication",
            "Tests considered investigational and not medically necessary",
            "Applies to all cancer types and stages",
            "Lack of comparative studies demonstrating improved health outcomes"
          ],
          "testsExplicitlyMentioned": [
            "Signatera - denied coverage",
            "RaDaR - denied coverage"
          ],
          "significantChanges": [
            "This appears to be a new policy (status: New, publish date 07/06/2022)",
            "Creates specific policy exclusions for hybrid personalized MRD testing",
            "References related policies for broader liquid biopsy and genetic testing coverage"
          ],
          "confidence": 0.95
        },
        "extraction": {
          "stance": "denies",
          "stanceConfidence": 0.7,
          "cancerTypes": [
            "All"
          ],
          "priorAuth": "unknown",
          "effectiveDate": null
        },
        "change": {
          "priority": "high",
          "changedHashes": [
            "new_document"
          ],
          "summary": "[HIGH] Changed: New document"
        },
        "delegationDetected": false,
        "artifactId": {
          "artifactId": "anthem_anthem-gene-59_2026-02-05_404195f9e6bf",
          "artifactPath": "data/artifacts/anthem/anthem_anthem-gene-59_2026-02-05_404195f9e6bf",
          "contentHash": "404195f9e6bffcab3d11f23759e8e7468336be7617efcdbd986b199c8c0e9796"
        },
        "pdfDiff": {
          "summary": "New document: 0 PLA codes, 0 CPT codes, 2 named tests.",
          "addedCodes": {
            "pla": [],
            "cpt": [],
            "hcpcs": []
          },
          "removedCodes": {
            "pla": [],
            "cpt": [],
            "hcpcs": []
          }
        }
      },
      "status": "ignored"
    },
    {
      "submissionId": "sub-2026-mlg093hs7ghs",
      "source": "payers",
      "type": "payer_policy_update",
      "title": "Humana: Humana Medical Coverage Policies Search Updated",
      "summary": "This document is an index page listing Humana's medical coverage policies with effective dates and review dates. While it references a 'Minimal Residual Disease Testing - Medicare Advantage' policy effective 8/1/2025, no specific coverage decisions or criteria for ctDNA/liquid biopsy tests are provided in this index.",
      "url": "https://mcp.humana.com/tad/tad_new/Search.aspx?docbegin=M&policyType=medical&searchtype=beginswith",
      "detectedAt": "2026-02-05T20:09:43.324Z",
      "triageHint": {
        "daemonScore": 8,
        "reason": "",
        "suggestedAction": "coverage_update",
        "suggestedTestName": null,
        "confidence": 0.85
      },
      "metadata": {
        "payerId": "humana",
        "payerName": "Humana",
        "policyId": "humana-mcp-search",
        "policyName": "Humana Medical Coverage Policies Search",
        "policyType": "molecular_oncology",
        "docType": "index_page",
        "contentType": "html",
        "testsFound": [],
        "isNewPolicy": true,
        "analysis": {
          "summary": "This document is an index page listing Humana's medical coverage policies with effective dates and review dates. While it references a 'Minimal Residual Disease Testing - Medicare Advantage' policy effective 8/1/2025, no specific coverage decisions or criteria for ctDNA/liquid biopsy tests are provided in this index.",
          "coverageStatus": "unclear",
          "keyConditions": [],
          "testsExplicitlyMentioned": [
            "Minimal Residual Disease Testing"
          ],
          "significantChanges": [
            "MRD testing policy was reviewed on 7/8/2025 with an effective date of 8/1/2025, indicating recent policy activity"
          ],
          "confidence": 0.3
        },
        "extraction": {
          "stance": "unclear",
          "stanceConfidence": 0.3,
          "cancerTypes": [
            "Prostate"
          ],
          "priorAuth": "unknown",
          "effectiveDate": null
        },
        "change": {
          "priority": "high",
          "changedHashes": [
            "new_document"
          ],
          "summary": "[HIGH] Changed: New document"
        },
        "delegationDetected": false,
        "artifactId": {
          "artifactId": "humana_humana-mcp-search_2026-02-05_7c460e63db50",
          "artifactPath": "data/artifacts/humana/humana_humana-mcp-search_2026-02-05_7c460e63db50",
          "contentHash": "7c460e63db50b188d1a4808b1bb3f5423160fd2be7e3be9282e6a8d028ba2900"
        },
        "pdfDiff": null
      },
      "status": "ignored"
    },
    {
      "submissionId": "sub-2026-mlg093htcum8",
      "source": "payers",
      "type": "payer_policy_update",
      "title": "EviCore (Evernorth): Liquid Biopsy Testing V2.0.2025 (MOL.TS.194.A) Updated",
      "summary": "EviCore's policy provides limited coverage for liquid biopsy testing, approving only FDA companion diagnostic assays for appropriate cancer types, Guardant360 LDT for metastatic NSCLC when tissue is unavailable, and ESR1 testing for hormone-positive breast cancer. All other non-companion diagnostic liquid biopsy tests are considered experimental/investigational and denied coverage.",
      "url": "https://www.evicore.com/sites/default/files/clinical-guidelines/2025-06/MOL.TS_.194.A%20Liquid%20Biopsy%20Testing_V2.0.2025_eff07.01.2025_pub04.08.2025_upd05.06.2025_upd06.02.2025.pdf",
      "detectedAt": "2026-02-05T20:09:43.327Z",
      "triageHint": {
        "daemonScore": 8,
        "reason": "",
        "suggestedAction": "coverage_update",
        "suggestedTestName": null,
        "confidence": 0.85
      },
      "metadata": {
        "payerId": "evicore",
        "payerName": "EviCore (Evernorth)",
        "policyId": "evicore-liquid-biopsy-2025-v2",
        "policyName": "Liquid Biopsy Testing V2.0.2025 (MOL.TS.194.A)",
        "policyType": "liquid_biopsy",
        "docType": "lbm_guideline",
        "contentType": "pdf",
        "testsFound": [
          "trm-1",
          "tds-23"
        ],
        "isNewPolicy": true,
        "analysis": {
          "summary": "EviCore's policy provides limited coverage for liquid biopsy testing, approving only FDA companion diagnostic assays for appropriate cancer types, Guardant360 LDT for metastatic NSCLC when tissue is unavailable, and ESR1 testing for hormone-positive breast cancer. All other non-companion diagnostic liquid biopsy tests are considered experimental/investigational and denied coverage.",
          "coverageStatus": "restricts",
          "keyConditions": [
            "FDA-approved companion diagnostic required with specific cancer type indication",
            "No previous somatic/germline testing for same mutations",
            "For Guardant360 LDT: metastatic NSCLC with insufficient tissue and contraindications to tissue biopsy",
            "For ESR1 testing: metastatic ER+/HER2- breast cancer with progression on endocrine therapy",
            "Qualified laboratory provider required"
          ],
          "testsExplicitlyMentioned": [
            "Guardant360 CDx (covered as companion diagnostic)",
            "Guardant360 LDT (restricted to metastatic NSCLC only)",
            "FoundationOne Liquid CDx (covered as companion diagnostic)"
          ],
          "significantChanges": [
            "MRD testing code 81479 listed in procedures but no coverage criteria provided, suggesting denial",
            "Broad categorical denial of non-CDx liquid biopsy tests as experimental/investigational"
          ],
          "confidence": 0.85
        },
        "extraction": {
          "stance": "denies",
          "stanceConfidence": 0.8,
          "cancerTypes": [
            "All",
            "NSCLC"
          ],
          "priorAuth": "required",
          "effectiveDate": null
        },
        "change": {
          "priority": "high",
          "changedHashes": [
            "new_document"
          ],
          "summary": "[HIGH] Changed: New document"
        },
        "delegationDetected": true,
        "artifactId": {
          "artifactId": "evicore_evicore-liquid-biopsy-2025-v2_2026-02-05_89600bfa7192",
          "artifactPath": "data/artifacts/evicore/evicore_evicore-liquid-biopsy-2025-v2_2026-02-05_89600bfa7192",
          "contentHash": "89600bfa7192dfbd6756b0230bdea87d6d17416fe28bf7f34156775f44ead44f"
        },
        "pdfDiff": {
          "summary": "New document: 4 PLA codes, 25 CPT codes, 1 named tests.",
          "addedCodes": {
            "pla": [
              "0388U",
              "0409U",
              "0530U",
              "0571U"
            ],
            "cpt": [
              "81168",
              "81235",
              "81237",
              "81245",
              "81246",
              "81276",
              "81278",
              "81279",
              "81338",
              "81347",
              "81348",
              "81357",
              "81360",
              "81401",
              "81402",
              "81403",
              "81405",
              "81406",
              "81407",
              "81408",
              "81450",
              "81462",
              "81463",
              "81464",
              "81479"
            ],
            "hcpcs": [
              "S1470"
            ]
          },
          "removedCodes": {
            "pla": [],
            "cpt": [],
            "hcpcs": []
          }
        }
      },
      "status": "ignored"
    },
    {
      "submissionId": "sub-2026-mlg093htupli",
      "source": "payers",
      "type": "payer_policy_update",
      "title": "EviCore (Evernorth): eviCore Clinical Guidelines Index (Johns Hopkins example) Updated",
      "summary": "This document is an index page for EviCore clinical guidelines that does not contain specific coverage policies or positions on ctDNA/liquid biopsy testing. It serves as a navigation portal to access actual clinical guidelines and notes that specific health plan policies may take precedence over EviCore guidelines.",
      "url": "https://www.evicore.com/provider/clinical-guidelines-details?hPlan=Johns+Hopkins+Healthcare&solution=laboratory+management",
      "detectedAt": "2026-02-05T20:09:43.329Z",
      "triageHint": {
        "daemonScore": 3,
        "reason": "",
        "suggestedAction": "coverage_update",
        "suggestedTestName": null,
        "confidence": 0.35
      },
      "metadata": {
        "payerId": "evicore",
        "payerName": "EviCore (Evernorth)",
        "policyId": "evicore-index-jhh",
        "policyName": "eviCore Clinical Guidelines Index (Johns Hopkins example)",
        "policyType": "liquid_biopsy",
        "docType": "index_page",
        "contentType": "html",
        "testsFound": [],
        "isNewPolicy": true,
        "analysis": {
          "summary": "This document is an index page for EviCore clinical guidelines that does not contain specific coverage policies or positions on ctDNA/liquid biopsy testing. It serves as a navigation portal to access actual clinical guidelines and notes that specific health plan policies may take precedence over EviCore guidelines.",
          "coverageStatus": "unclear",
          "keyConditions": [],
          "testsExplicitlyMentioned": [],
          "significantChanges": [
            "Website upgrade mentioned with note that bookmarked guidelines might have changed locations"
          ],
          "confidence": 0.95
        },
        "extraction": {
          "stance": "unclear",
          "stanceConfidence": 0.3,
          "cancerTypes": [],
          "priorAuth": "unknown",
          "effectiveDate": null
        },
        "change": {
          "priority": "high",
          "changedHashes": [
            "new_document"
          ],
          "summary": "[HIGH] Changed: New document"
        },
        "delegationDetected": false,
        "artifactId": {
          "artifactId": "evicore_evicore-index-jhh_2026-02-05_8d91d11468a5",
          "artifactPath": "data/artifacts/evicore/evicore_evicore-index-jhh_2026-02-05_8d91d11468a5",
          "contentHash": "8d91d11468a54b61cf7da66ddd7c0f163861d4b2548d6a0e29097ac3878c3cd0"
        },
        "pdfDiff": null
      },
      "status": "ignored"
    },
    {
      "submissionId": "sub-2026-mlg093htr0qc",
      "source": "payers",
      "type": "payer_policy_update",
      "title": "Carelon (formerly AIM Specialty Health): Genetic Liquid Biopsy in Cancer Management - Landing Page Updated",
      "summary": "Carelon's policy appears to restrict genetic liquid biopsy testing for cancer management and surveillance, with the truncated document establishing strict general requirements but not providing complete coverage criteria. The policy explicitly states that genetic tests not specifically mentioned in the guidelines are considered not medically necessary.",
      "url": "https://guidelines.carelonmedicalbenefitsmanagement.com/genetic-liquid-biopsy-in-the-management-of-cancer-and-cancer-surveillance-2025-11-15-updated-2026-01-01/",
      "detectedAt": "2026-02-05T20:09:43.331Z",
      "triageHint": {
        "daemonScore": 8,
        "reason": "",
        "suggestedAction": "coverage_update",
        "suggestedTestName": null,
        "confidence": 0.85
      },
      "metadata": {
        "payerId": "carelon",
        "payerName": "Carelon (formerly AIM Specialty Health)",
        "policyId": "carelon-liquid-biopsy-landing",
        "policyName": "Genetic Liquid Biopsy in Cancer Management - Landing Page",
        "policyType": "liquid_biopsy",
        "docType": "index_page",
        "contentType": "html",
        "testsFound": [
          "mrd-7",
          "mrd-6",
          "mrd-14",
          "ecd-2",
          "mced"
        ],
        "isNewPolicy": true,
        "analysis": {
          "summary": "Carelon's policy appears to restrict genetic liquid biopsy testing for cancer management and surveillance, with the truncated document establishing strict general requirements but not providing complete coverage criteria. The policy explicitly states that genetic tests not specifically mentioned in the guidelines are considered not medically necessary.",
          "coverageStatus": "restricts",
          "keyConditions": [
            "Genomic testing must have established analytical and clinical validity",
            "Must be performed in appropriately certified laboratory",
            "Repeated testing limited to evaluation following intervention or clinical status changes",
            "Genetic tests not specifically mentioned in guidelines considered not medically necessary",
            "May require peer-to-peer conversation for multiple simultaneous interventions"
          ],
          "testsExplicitlyMentioned": [
            "signatera",
            "guardant-reveal",
            "navdx",
            "galleri",
            "mced"
          ],
          "significantChanges": [
            "Policy updated with new codes effective January 1, 2026",
            "Document shows effective date of November 15, 2025 with update to January 1, 2026"
          ],
          "confidence": 0.6
        },
        "extraction": {
          "stance": "denies",
          "stanceConfidence": 0.8,
          "cancerTypes": [],
          "priorAuth": "not_required",
          "effectiveDate": "2025-11-15"
        },
        "change": {
          "priority": "high",
          "changedHashes": [
            "new_document"
          ],
          "summary": "[HIGH] Changed: New document"
        },
        "delegationDetected": false,
        "artifactId": {
          "artifactId": "carelon_carelon-liquid-biopsy-landing_2026-02-05_4d734edd7856",
          "artifactPath": "data/artifacts/carelon/carelon_carelon-liquid-biopsy-landing_2026-02-05_4d734edd7856",
          "contentHash": "4d734edd78561c825fd9219d7283fe73988e1475ca5b6ea4f26774be0e31efa5"
        },
        "pdfDiff": null
      },
      "status": "ignored"
    },
    {
      "submissionId": "sub-2026-mlg093ht4c8r",
      "source": "payers",
      "type": "payer_policy_update",
      "title": "Blue Shield of California: Tumor-Informed ctDNA Testing for Cancer Management (BSC2.18) Updated",
      "summary": "Blue Shield of California provides coverage for tumor-informed ctDNA testing (including Signatera and Guardant-Reveal/PCM) for post-surgical cancer management, but with strict criteria requiring stage I-IV cancer after curative surgery and adherence to NCCN monitoring frequency guidelines. The policy specifically supports MRD testing for treatment decisions and recurrence monitoring but considers it investigational in certain conditions like pregnancy and active hematological malignancy.",
      "url": "https://www.blueshieldca.com/content/dam/bsca/en/provider/documents/2023/authorizations/PRV_Tumor_Informed_Circulating_Tumor_DNA_Test_Cancer_Mng.pdf",
      "detectedAt": "2026-02-05T20:09:43.335Z",
      "triageHint": {
        "daemonScore": 8,
        "reason": "",
        "suggestedAction": "coverage_update",
        "suggestedTestName": null,
        "confidence": 0.85
      },
      "metadata": {
        "payerId": "blueshieldca",
        "payerName": "Blue Shield of California",
        "policyId": "bsca-tumor-informed-ctdna-um",
        "policyName": "Tumor-Informed ctDNA Testing for Cancer Management (BSC2.18)",
        "policyType": "mrd",
        "docType": "um_criteria",
        "contentType": "pdf",
        "testsFound": [
          "mrd-7",
          "mrd-6"
        ],
        "isNewPolicy": true,
        "analysis": {
          "summary": "Blue Shield of California provides coverage for tumor-informed ctDNA testing (including Signatera and Guardant-Reveal/PCM) for post-surgical cancer management, but with strict criteria requiring stage I-IV cancer after curative surgery and adherence to NCCN monitoring frequency guidelines. The policy specifically supports MRD testing for treatment decisions and recurrence monitoring but considers it investigational in certain conditions like pregnancy and active hematological malignancy.",
          "coverageStatus": "restricts",
          "keyConditions": [
            "Stage I-IV cancer after surgical intervention with curative intent",
            "Testing for adjuvant/targeted therapy decisions or monitoring for relapse/progression",
            "Must follow NCCN frequency guidelines (initial testing within 4-6 weeks post-surgery, then varying schedules by cancer type)",
            "Maximum testing frequency limits (4 tests/year initially, reducing over time)",
            "Excluded conditions: pregnancy, active hematological malignancy, recent bone marrow transplant, within 2 weeks of blood transfusion"
          ],
          "testsExplicitlyMentioned": [
            "Signatera (covered with restrictions - CPT 0340U)",
            "Guardant-Reveal/PCM (covered with restrictions - CPT 0306U, 0307U)"
          ],
          "significantChanges": [
            "Policy effective March 1, 2023 (original June 1, 2022)",
            "Addition of specific CPT codes for Signatera (0340U) effective October 1, 2022",
            "Addition of PCM codes (0306U, 0307U) effective April 1, 2022",
            "Detailed frequency limitations and monitoring schedules established"
          ],
          "confidence": 0.95
        },
        "extraction": {
          "stance": "denies",
          "stanceConfidence": 0.8,
          "cancerTypes": [
            "Breast",
            "CRC",
            "Lung",
            "Prostate"
          ],
          "priorAuth": "unknown",
          "effectiveDate": "2023-03-01"
        },
        "change": {
          "priority": "high",
          "changedHashes": [
            "new_document"
          ],
          "summary": "[HIGH] Changed: New document"
        },
        "delegationDetected": false,
        "artifactId": {
          "artifactId": "blueshieldca_bsca-tumor-informed-ctdna-um_2026-02-05_4bd86ea1bb9c",
          "artifactPath": "data/artifacts/blueshieldca/blueshieldca_bsca-tumor-informed-ctdna-um_2026-02-05_4bd86ea1bb9c",
          "contentHash": "4bd86ea1bb9c8d4b14e66f60e07e11a8e90453130346a1c6af1e928c84a3dd0d"
        },
        "pdfDiff": {
          "summary": "New document: 3 PLA codes, 1 CPT codes, 3 named tests.",
          "addedCodes": {
            "pla": [
              "0306U",
              "0307U",
              "0340U"
            ],
            "cpt": [
              "81479"
            ],
            "hcpcs": []
          },
          "removedCodes": {
            "pla": [],
            "cpt": [],
            "hcpcs": []
          }
        }
      },
      "status": "ignored"
    },
    {
      "submissionId": "sub-2026-mlg093hta6sb",
      "source": "payers",
      "type": "payer_policy_update",
      "title": "BCBS Louisiana: Tumor Informed Circulating Tumor DNA Testing for Cancer Management (00792) - RETIRED Updated",
      "summary": "This BCBS Louisiana policy for ctDNA MRD testing has been retired as of July 1, 2024, with coverage decisions now managed through Carelon MBM Genetic Testing Program. The document does not provide any coverage position details as it only announces the retirement of the policy.",
      "url": "https://www.lablue.com/-/media/Medical%20Policies/2022/07/11/17/15/Tumor%20Informed%20Circulating%20Tumor%20DNA%20Testing%20for%20Cancer%20Management%2000792%2020220711_accessibile%20pdf.pdf",
      "detectedAt": "2026-02-05T20:09:43.338Z",
      "triageHint": {
        "daemonScore": 3,
        "reason": "",
        "suggestedAction": "coverage_update",
        "suggestedTestName": null,
        "confidence": 0.35
      },
      "metadata": {
        "payerId": "bcbsla",
        "payerName": "BCBS Louisiana",
        "policyId": "bcbsla-ctdna-mrd-retired",
        "policyName": "Tumor Informed Circulating Tumor DNA Testing for Cancer Management (00792) - RETIRED",
        "policyType": "mrd",
        "docType": "provider_bulletin",
        "contentType": "pdf",
        "testsFound": [],
        "isNewPolicy": true,
        "analysis": {
          "summary": "This BCBS Louisiana policy for ctDNA MRD testing has been retired as of July 1, 2024, with coverage decisions now managed through Carelon MBM Genetic Testing Program. The document does not provide any coverage position details as it only announces the retirement of the policy.",
          "coverageStatus": "unclear",
          "keyConditions": [],
          "testsExplicitlyMentioned": [],
          "significantChanges": [
            "Policy retired effective 07/01/2024",
            "Coverage decisions transferred to Carelon MBM Genetic Testing Program as part of collaborative partnership"
          ],
          "confidence": 0.9
        },
        "extraction": {
          "stance": "unclear",
          "stanceConfidence": 0.3,
          "cancerTypes": [],
          "priorAuth": "unknown",
          "effectiveDate": "2022-07-11"
        },
        "change": {
          "priority": "high",
          "changedHashes": [
            "new_document"
          ],
          "summary": "[HIGH] Changed: New document"
        },
        "delegationDetected": true,
        "artifactId": {
          "artifactId": "bcbsla_bcbsla-ctdna-mrd-retired_2026-02-05_2e4ee21b949c",
          "artifactPath": "data/artifacts/bcbsla/bcbsla_bcbsla-ctdna-mrd-retired_2026-02-05_2e4ee21b949c",
          "contentHash": "2e4ee21b949cfc2be6c37a279dbc7df647c217a0558af4ae71c70068e6774cac"
        },
        "pdfDiff": {
          "summary": "New document: 0 PLA codes, 0 CPT codes, 1 named tests.",
          "addedCodes": {
            "pla": [],
            "cpt": [],
            "hcpcs": []
          },
          "removedCodes": {
            "pla": [],
            "cpt": [],
            "hcpcs": []
          }
        }
      },
      "status": "ignored"
    },
    {
      "submissionId": "sub-2026-mlg093htg9mn",
      "source": "payers",
      "type": "payer_policy_update",
      "title": "Geisinger Health Plan: Minimal Residual Disease NGS Testing (MP360) Updated",
      "summary": "Geisinger Health Plan provides limited coverage for specific MRD tests under strict conditions, but the overall stance appears restrictive with many exclusions. Coverage is provided for named tests like Signatera, ClonoSeq, Guardant Reveal, and NavDx only for specific cancer types and clinical scenarios, while explicitly excluding unlisted MRD NGS tests.",
      "url": "https://www.geisinger.org/-/media/OneGeisinger/Files/Policy-PDFs/MP/351-400/MP360-Minimal-Residual-Disease-NGS-Testing.pdf",
      "detectedAt": "2026-02-05T20:09:43.339Z",
      "triageHint": {
        "daemonScore": 8,
        "reason": "",
        "suggestedAction": "coverage_update",
        "suggestedTestName": null,
        "confidence": 0.85
      },
      "metadata": {
        "payerId": "geisinger",
        "payerName": "Geisinger Health Plan",
        "policyId": "geisinger-mp360-mrd",
        "policyName": "Minimal Residual Disease NGS Testing (MP360)",
        "policyType": "mrd",
        "docType": "um_criteria",
        "contentType": "pdf",
        "testsFound": [
          "mrd-7",
          "mrd-6",
          "mrd-14",
          "mrd-19",
          "mrd-1"
        ],
        "isNewPolicy": true,
        "analysis": {
          "summary": "Geisinger Health Plan provides limited coverage for specific MRD tests under strict conditions, but the overall stance appears restrictive with many exclusions. Coverage is provided for named tests like Signatera, ClonoSeq, Guardant Reveal, and NavDx only for specific cancer types and clinical scenarios, while explicitly excluding unlisted MRD NGS tests.",
          "coverageStatus": "restricts",
          "keyConditions": [
            "Coverage limited to specific named tests (Signatera, ClonoSeq, Guardant Reveal, NavDx)",
            "Specific cancer type requirements (CRC stage II-IV, breast cancer stage II-IV, multiple myeloma, acute leukemias, etc.)",
            "Must be used in conjunction with other clinical and molecular data",
            "Frequency limitations specified for each test type",
            "Testing only after curative-intent treatment or at specific treatment phases",
            "Medicare coverage follows CMS local carrier determinations (Palmetto GBA L38779/A58376)"
          ],
          "testsExplicitlyMentioned": [
            "signatera - covered for specific solid tumors and stages",
            "clonoseq - covered for hematologic malignancies",
            "guardant-reveal - covered for stage I-III breast and colorectal cancer monitoring",
            "navdx - covered for HPV-driven oropharyngeal cancer surveillance"
          ],
          "significantChanges": [
            "Policy effective date 2021-12-26 suggests this may be establishing new MRD coverage criteria",
            "References Medicare coverage policy established by Palmetto GBA on 12/26/2021"
          ],
          "confidence": 0.85
        },
        "extraction": {
          "stance": "denies",
          "stanceConfidence": 0.8,
          "cancerTypes": [
            "Bladder",
            "Breast",
            "CRC",
            "Leukemia",
            "Lymphoma",
            "Myeloma",
            "Solid tumor"
          ],
          "priorAuth": "unknown",
          "effectiveDate": "2021-12-26"
        },
        "change": {
          "priority": "high",
          "changedHashes": [
            "new_document"
          ],
          "summary": "[HIGH] Changed: New document"
        },
        "delegationDetected": false,
        "artifactId": {
          "artifactId": "geisinger_geisinger-mp360-mrd_2026-02-05_30395edac728",
          "artifactPath": "data/artifacts/geisinger/geisinger_geisinger-mp360-mrd_2026-02-05_30395edac728",
          "contentHash": "30395edac728bf879718e2e617f780b38725660d0a3edd47e88aaf75a587623c"
        },
        "pdfDiff": {
          "summary": "New document: 14 PLA codes, 3 CPT codes, 7 named tests.",
          "addedCodes": {
            "pla": [
              "0285U",
              "0306U",
              "0307U",
              "0340U",
              "0356U",
              "0364U",
              "0470U",
              "0502U",
              "0543U",
              "0558U",
              "0559U",
              "0560U",
              "0561U",
              "0569U"
            ],
            "cpt": [
              "81445",
              "81450",
              "81479"
            ],
            "hcpcs": [
              "G2124"
            ]
          },
          "removedCodes": {
            "pla": [],
            "cpt": [],
            "hcpcs": []
          }
        }
      },
      "status": "ignored"
    },
    {
      "submissionId": "sub-2026-mlg093htexjv",
      "source": "payers",
      "type": "payer_policy_update",
      "title": "Geisinger Health Plan: Policy Updates - February 2025 Updated",
      "summary": "This policy bulletin does not contain any coverage updates or decisions regarding ctDNA, liquid biopsy, or MRD testing. Despite the pre-extracted data indicating the presence of tests like Signatera, Guardant-Reveal, ClonSEQ, Galleri, and MCED, the actual document content focuses on unrelated policies including deep brain stimulation, organ transplant rejection testing, and genetic testing for colorectal cancer.",
      "url": "https://www.geisinger.org/-/media/onegeisinger/files/policy-pdfs/whats-new-updates/whats-new-february-2025.pdf",
      "detectedAt": "2026-02-05T20:09:43.341Z",
      "triageHint": {
        "daemonScore": 8,
        "reason": "",
        "suggestedAction": "coverage_update",
        "suggestedTestName": null,
        "confidence": 0.85
      },
      "metadata": {
        "payerId": "geisinger",
        "payerName": "Geisinger Health Plan",
        "policyId": "geisinger-whats-new-feb2025",
        "policyName": "Policy Updates - February 2025",
        "policyType": "mrd",
        "docType": "provider_bulletin",
        "contentType": "pdf",
        "testsFound": [
          "mrd-7",
          "mrd-6",
          "mrd-19",
          "ecd-2",
          "mced"
        ],
        "isNewPolicy": true,
        "analysis": {
          "summary": "This policy bulletin does not contain any coverage updates or decisions regarding ctDNA, liquid biopsy, or MRD testing. Despite the pre-extracted data indicating the presence of tests like Signatera, Guardant-Reveal, ClonSEQ, Galleri, and MCED, the actual document content focuses on unrelated policies including deep brain stimulation, organ transplant rejection testing, and genetic testing for colorectal cancer.",
          "coverageStatus": "unclear",
          "keyConditions": [],
          "testsExplicitlyMentioned": [],
          "significantChanges": [],
          "confidence": 0.95
        },
        "extraction": {
          "stance": "denies",
          "stanceConfidence": 0.8,
          "cancerTypes": [
            "Endometrial",
            "Solid tumor"
          ],
          "priorAuth": "unknown",
          "effectiveDate": "2025-03-15"
        },
        "change": {
          "priority": "high",
          "changedHashes": [
            "new_document"
          ],
          "summary": "[HIGH] Changed: New document"
        },
        "delegationDetected": false,
        "artifactId": {
          "artifactId": "geisinger_geisinger-whats-new-feb2025_2026-02-05_d44d3d92c0ca",
          "artifactPath": "data/artifacts/geisinger/geisinger_geisinger-whats-new-feb2025_2026-02-05_d44d3d92c0ca",
          "contentHash": "d44d3d92c0cae4f05629be9f26b4b1f018812d9eaf09fca0f1becea773c8b689"
        },
        "pdfDiff": {
          "summary": "New document: 12 PLA codes, 1 CPT codes, 6 named tests.",
          "addedCodes": {
            "pla": [
              "0206U",
              "0207U",
              "0289U",
              "0340U",
              "0346U",
              "0358U",
              "0359U",
              "0364U",
              "0403U",
              "0412U",
              "0445U",
              "0459U"
            ],
            "cpt": [
              "81406"
            ],
            "hcpcs": []
          },
          "removedCodes": {
            "pla": [],
            "cpt": [],
            "hcpcs": []
          }
        }
      },
      "status": "ignored"
    },
    {
      "submissionId": "sub-2026-mlg093htejlk",
      "source": "payers",
      "type": "payer_policy_update",
      "title": "BCBS Tennessee: Circulating Tumor DNA (Liquid Biopsy) Updated",
      "summary": "BCBS Tennessee covers circulating tumor DNA (liquid biopsy) companion diagnostic assays as medically necessary when specific criteria are met. Coverage is limited to FDA-approved tests like FoundationOne Liquid CDx and Guardant360 CDx for advanced/metastatic solid tumors when companion diagnostic testing is required by FDA labeling and no previous somatic tumor testing has been performed.",
      "url": "https://www.bcbst.com/mpmanual/!ssl!/webhelp/Circulating_Tumor_DNA_Liquid_Biopsy.htm",
      "detectedAt": "2026-02-05T20:09:43.343Z",
      "triageHint": {
        "daemonScore": 8,
        "reason": "",
        "suggestedAction": "coverage_update",
        "suggestedTestName": null,
        "confidence": 0.85
      },
      "metadata": {
        "payerId": "bcbst",
        "payerName": "BCBS Tennessee",
        "policyId": "bcbst-ctdna-liquid-biopsy",
        "policyName": "Circulating Tumor DNA (Liquid Biopsy)",
        "policyType": "liquid_biopsy",
        "contentType": "static_html",
        "testsFound": [
          "trm-1",
          "tds-2"
        ],
        "isNewPolicy": true,
        "analysis": {
          "summary": "BCBS Tennessee covers circulating tumor DNA (liquid biopsy) companion diagnostic assays as medically necessary when specific criteria are met. Coverage is limited to FDA-approved tests like FoundationOne Liquid CDx and Guardant360 CDx for advanced/metastatic solid tumors when companion diagnostic testing is required by FDA labeling and no previous somatic tumor testing has been performed.",
          "coverageStatus": "supports",
          "keyConditions": [
            "Diagnosis of advanced or metastatic cancer (solid tumors)",
            "Treatment with medication requiring FDA-approved liquid biopsy-based companion diagnostic",
            "FDA label for drug/indication states companion diagnostic testing is necessary",
            "No previous somatic tumor testing to identify genetic changes required for medication"
          ],
          "testsExplicitlyMentioned": [
            "FoundationOne Liquid CDx - covered as medically necessary when criteria met",
            "Guardant360 CDx - covered as medically necessary when criteria met"
          ],
          "significantChanges": [
            "New policy effective 9/30/2025 establishing coverage for liquid biopsy companion diagnostics",
            "Restricts coverage to FDA-approved companion diagnostic assays only",
            "Requires absence of previous somatic tumor testing as prerequisite"
          ],
          "confidence": 0.95
        },
        "extraction": {
          "stance": "supports",
          "stanceConfidence": 0.9,
          "cancerTypes": [],
          "priorAuth": "unknown",
          "effectiveDate": "2025-09-30"
        },
        "change": {
          "priority": "high",
          "changedHashes": [
            "new_document"
          ],
          "summary": "[HIGH] Changed: New document"
        },
        "delegationDetected": false,
        "artifactId": {
          "artifactId": "bcbst_bcbst-ctdna-liquid-biopsy_2026-02-05_d05542ad08ef",
          "artifactPath": "data/artifacts/bcbst/bcbst_bcbst-ctdna-liquid-biopsy_2026-02-05_d05542ad08ef",
          "contentHash": "d05542ad08eff96ea9f59066b1a49319fa0b6e474128e7ddf70d232edf55a01b"
        },
        "pdfDiff": null
      },
      "status": "ignored"
    },
    {
      "submissionId": "sub-2026-mlg093ht6635",
      "source": "payers",
      "type": "payer_policy_update",
      "title": "Blue Cross MA: Circulating Tumor DNA and Circulating Tumor Cells for Cancer Updated",
      "summary": "Blue Cross MA covers Guardant360 liquid biopsy testing specifically for Stage IIIB/IV NSCLC patients when tissue-based testing is infeasible or for patients progressing on certain therapies, but considers all other plasma-based CGP tests and ctDNA applications investigational. Circulating tumor cells testing is deemed investigational for all indications.",
      "url": "https://www.bluecrossma.org/medical-policies/sites/g/files/csphws2091/files/acquiadam-assets/797Circulating_Tumor_DNA_For_Cancer.pdf",
      "detectedAt": "2026-02-05T20:09:43.344Z",
      "triageHint": {
        "daemonScore": 8,
        "reason": "",
        "suggestedAction": "coverage_update",
        "suggestedTestName": null,
        "confidence": 0.85
      },
      "metadata": {
        "payerId": "bcbsma",
        "payerName": "Blue Cross MA",
        "policyId": "bcbsma-ctdna-797",
        "policyName": "Circulating Tumor DNA and Circulating Tumor Cells for Cancer",
        "policyType": "liquid_biopsy",
        "contentType": "pdf",
        "testsFound": [
          "trm-1"
        ],
        "isNewPolicy": true,
        "analysis": {
          "summary": "Blue Cross MA covers Guardant360 liquid biopsy testing specifically for Stage IIIB/IV NSCLC patients when tissue-based testing is infeasible or for patients progressing on certain therapies, but considers all other plasma-based CGP tests and ctDNA applications investigational. Circulating tumor cells testing is deemed investigational for all indications.",
          "coverageStatus": "restricts",
          "keyConditions": [
            "Limited to Stage IIIB/IV NSCLC patients only",
            "Tissue-based CGP must be infeasible (insufficient quantity or medically contraindicated)",
            "Prior results for EGFR, ALK, ROS1, and PDL1 tests must not be available",
            "Applies to patients progressing on chemotherapy/immunotherapy without prior genetic testing",
            "Covers patients progressing on EGFR tyrosine kinase inhibitors",
            "Prior authorization required through AIM Specialty Health",
            "If ctDNA insufficient/not detected, tissue-based genotyping should be considered"
          ],
          "testsExplicitlyMentioned": [
            "Guardant360 - medically necessary for specific NSCLC indications only"
          ],
          "significantChanges": [
            "Policy was reactivated in June 2020 after being inactive",
            "Prior authorization requirement clarified to be through AIM Specialty Health",
            "Medicare coverage information removed in January 2021"
          ],
          "confidence": 0.95
        },
        "extraction": {
          "stance": "denies",
          "stanceConfidence": 0.5999999999999999,
          "cancerTypes": [
            "All",
            "NSCLC",
            "Prostate"
          ],
          "priorAuth": "required",
          "effectiveDate": "2020-06-08"
        },
        "change": {
          "priority": "high",
          "changedHashes": [
            "new_document"
          ],
          "summary": "[HIGH] Changed: New document"
        },
        "delegationDetected": false,
        "artifactId": {
          "artifactId": "bcbsma_bcbsma-ctdna-797_2026-02-05_e4bfb11dc3a5",
          "artifactPath": "data/artifacts/bcbsma/bcbsma_bcbsma-ctdna-797_2026-02-05_e4bfb11dc3a5",
          "contentHash": "e4bfb11dc3a514209c08aa2670addd50eaa5bfd78cf6636412e6ba82ddc4c84e"
        },
        "pdfDiff": {
          "summary": "New document: 0 PLA codes, 3 CPT codes, 1 named tests.",
          "addedCodes": {
            "pla": [],
            "cpt": [
              "81445",
              "81450",
              "81455"
            ],
            "hcpcs": [
              "S0500"
            ]
          },
          "removedCodes": {
            "pla": [],
            "cpt": [],
            "hcpcs": []
          }
        }
      },
      "status": "ignored"
    },
    {
      "submissionId": "sub-2026-mlg093ht7sl0",
      "source": "payers",
      "type": "payer_policy_update",
      "title": "Excellus BCBS (NY): Circulating Tumor DNA for Management of Cancer (Liquid Biopsy) Updated",
      "summary": "Excellus BCBS covers ctDNA/liquid biopsy testing only for specific cancer types and targeted gene mutations when FDA-approved and used as an alternative to tissue biopsy when invasive biopsy is contraindicated. Comprehensive genomic profiling tests like FoundationOne Liquid CDx and Guardant 360 are explicitly considered investigational and not covered.",
      "url": "https://www.excellusbcbs.com/documents/d/global/exc-prv-circulating-tumor-dna-for-management-of-cancer-liquid-biopsy-",
      "detectedAt": "2026-02-05T20:09:43.346Z",
      "triageHint": {
        "daemonScore": 8,
        "reason": "",
        "suggestedAction": "coverage_update",
        "suggestedTestName": null,
        "confidence": 0.85
      },
      "metadata": {
        "payerId": "excellus",
        "payerName": "Excellus BCBS (NY)",
        "policyId": "excellus-ctdna-liquid-biopsy",
        "policyName": "Circulating Tumor DNA for Management of Cancer (Liquid Biopsy)",
        "policyType": "liquid_biopsy",
        "contentType": "pdf",
        "testsFound": [
          "trm-1",
          "tds-2",
          "ecd-7"
        ],
        "isNewPolicy": true,
        "analysis": {
          "summary": "Excellus BCBS covers ctDNA/liquid biopsy testing only for specific cancer types and targeted gene mutations when FDA-approved and used as an alternative to tissue biopsy when invasive biopsy is contraindicated. Comprehensive genomic profiling tests like FoundationOne Liquid CDx and Guardant 360 are explicitly considered investigational and not covered.",
          "coverageStatus": "restricts",
          "keyConditions": [
            "Must be FDA-approved for specific tumor type",
            "Used to direct targeted therapy",
            "Alternative to tissue biopsy when invasive biopsy contraindicated or insufficient tissue",
            "Results must guide patient management",
            "Limited to specific cancer types: metastatic colorectal, NSCLC, stage III/IV melanoma, metastatic pancreatic, ovarian, metastatic prostate, HR+/HER2- breast cancer",
            "Only for specified targeted gene mutations per cancer type",
            "Cannot be used in lieu of tissue diagnosis",
            "Should not test liquid biopsy and tissue simultaneously"
          ],
          "testsExplicitlyMentioned": [
            "FoundationOne Liquid CDx - considered investigational",
            "Guardant 360 - considered investigational"
          ],
          "significantChanges": [
            "Policy effective date is February 20, 2025, suggesting this is a recent update",
            "Explicit denial of comprehensive genomic profiling platforms including named tests"
          ],
          "confidence": 0.95
        },
        "extraction": {
          "stance": "denies",
          "stanceConfidence": 0.8,
          "cancerTypes": [
            "All",
            "Melanoma"
          ],
          "priorAuth": "unknown",
          "effectiveDate": "2025-02-20"
        },
        "change": {
          "priority": "high",
          "changedHashes": [
            "new_document"
          ],
          "summary": "[HIGH] Changed: New document"
        },
        "delegationDetected": false,
        "artifactId": {
          "artifactId": "excellus_excellus-ctdna-liquid-biopsy_2026-02-05_3bd184f2e668",
          "artifactPath": "data/artifacts/excellus/excellus_excellus-ctdna-liquid-biopsy_2026-02-05_3bd184f2e668",
          "contentHash": "3bd184f2e6680d08b1f7862644a972c4ccaee0fcf6dc4126a064e716d5ef756c"
        },
        "pdfDiff": {
          "summary": "New document: 21 PLA codes, 30 CPT codes, 7 named tests.",
          "addedCodes": {
            "pla": [
              "0177U",
              "0179U",
              "0229U",
              "0239U",
              "0242U",
              "0326U",
              "0337U",
              "0338U",
              "0388U",
              "0409U",
              "0485U",
              "0487U",
              "0490U",
              "0491U",
              "0498U",
              "0499U",
              "0530U",
              "0539U",
              "0562U",
              "0571U",
              "0585U"
            ],
            "cpt": [
              "81162",
              "81191",
              "81192",
              "81193",
              "81194",
              "81210",
              "81235",
              "81272",
              "81275",
              "81276",
              "81277",
              "81307",
              "81309",
              "81311",
              "81401",
              "81402",
              "81403",
              "81404",
              "81405",
              "81406",
              "81445",
              "81449",
              "81455",
              "81456",
              "81462",
              "81463",
              "81464",
              "81479",
              "86152",
              "86153"
            ],
            "hcpcs": [
              "S0003"
            ]
          },
          "removedCodes": {
            "pla": [],
            "cpt": [],
            "hcpcs": []
          }
        }
      },
      "status": "ignored"
    },
    {
      "submissionId": "sub-2026-mlg093htkbbd",
      "source": "payers",
      "type": "payer_policy_update",
      "title": "BlueCross BlueShield South Carolina: Liquid Biopsy Updated",
      "summary": "BlueCross BlueShield South Carolina covers ctDNA/liquid biopsy testing for specific cancer types (NSCLC, HR-positive/HER2-negative breast cancer, and castration-resistant prostate cancer) when tissue-based testing is inadequate or for specific biomarker analysis. However, they explicitly deny coverage for cancer screening tests like GRAIL Galleri and most other liquid biopsy applications not meeting their narrow criteria.",
      "url": "https://www.southcarolinablues.com/web/public/brands/medicalpolicy/external/external-policies/liquid-biopsy/",
      "detectedAt": "2026-02-05T20:09:43.347Z",
      "triageHint": {
        "daemonScore": 8,
        "reason": "",
        "suggestedAction": "coverage_update",
        "suggestedTestName": null,
        "confidence": 0.85
      },
      "metadata": {
        "payerId": "bcbssc",
        "payerName": "BlueCross BlueShield South Carolina",
        "policyId": "bcbssc-liquid-biopsy",
        "policyName": "Liquid Biopsy",
        "policyType": "liquid_biopsy",
        "contentType": "static_html",
        "testsFound": [
          "trm-1",
          "tds-23",
          "ecd-2",
          "mced"
        ],
        "isNewPolicy": true,
        "analysis": {
          "summary": "BlueCross BlueShield South Carolina covers ctDNA/liquid biopsy testing for specific cancer types (NSCLC, HR-positive/HER2-negative breast cancer, and castration-resistant prostate cancer) when tissue-based testing is inadequate or for specific biomarker analysis. However, they explicitly deny coverage for cancer screening tests like GRAIL Galleri and most other liquid biopsy applications not meeting their narrow criteria.",
          "coverageStatus": "restricts",
          "keyConditions": [
            "NSCLC: ctDNA testing when tissue-based testing infeasible or insufficient",
            "HR-positive/HER2-negative breast cancer: PIK3CA testing for targeted therapy consideration",
            "Castration-resistant prostate cancer: AR-V7 and BRCA1/2 testing",
            "Annual testing limit for qualifying individuals",
            "Must be for treatment selection, not screening or general monitoring"
          ],
          "testsExplicitlyMentioned": [
            "GRAIL Galleri - explicitly denied for screening",
            "CELLSEARCH CTC - denied as not medically necessary"
          ],
          "significantChanges": [
            "Policy effective 2024-01-01 suggests recent update",
            "Specific inclusion of PIK3CA testing for breast cancer",
            "Clear exclusion of liquid biopsy screening applications"
          ],
          "confidence": 0.85
        },
        "extraction": {
          "stance": "denies",
          "stanceConfidence": 0.7,
          "cancerTypes": [
            "All",
            "Breast",
            "NSCLC",
            "Prostate"
          ],
          "priorAuth": "unknown",
          "effectiveDate": "2024-01-01"
        },
        "change": {
          "priority": "high",
          "changedHashes": [
            "new_document"
          ],
          "summary": "[HIGH] Changed: New document"
        },
        "delegationDetected": false,
        "artifactId": {
          "artifactId": "bcbssc_bcbssc-liquid-biopsy_2026-02-05_ab8da767dd19",
          "artifactPath": "data/artifacts/bcbssc/bcbssc_bcbssc-liquid-biopsy_2026-02-05_ab8da767dd19",
          "contentHash": "ab8da767dd19c3558b8d567adad6d60c7a047512472e44fca06b76b89d53fe25"
        },
        "pdfDiff": null
      },
      "status": "ignored"
    },
    {
      "submissionId": "sub-2026-mlg093htqu1d",
      "source": "payers",
      "type": "payer_policy_update",
      "title": "FEP Blue (Federal Employee Program): Circulating Tumor DNA and Circulating Tumor Cells (2.04.141) Updated",
      "summary": "FEP Blue considers circulating tumor DNA and circulating tumor cells testing investigational for all indications covered in this general policy, though specific FDA-approved companion diagnostic tests for targeted therapies are covered under separate cancer-specific policies. The policy excludes many common clinical applications which are addressed in other more permissive policies.",
      "url": "https://www.fepblue.org/-/media/PDFs/Medical-Policies/2025/January/Medical-Policies/Remove-and-Replace/204141-Circulating-Tumor-DNA-and.pdf",
      "detectedAt": "2026-02-05T20:09:43.350Z",
      "triageHint": {
        "daemonScore": 8,
        "reason": "",
        "suggestedAction": "coverage_update",
        "suggestedTestName": null,
        "confidence": 0.85
      },
      "metadata": {
        "payerId": "fepblue",
        "payerName": "FEP Blue (Federal Employee Program)",
        "policyId": "fep-ctdna-204141",
        "policyName": "Circulating Tumor DNA and Circulating Tumor Cells (2.04.141)",
        "policyType": "liquid_biopsy",
        "contentType": "pdf",
        "testsFound": [
          "trm-1",
          "tds-2",
          "tds-23"
        ],
        "isNewPolicy": true,
        "analysis": {
          "summary": "FEP Blue considers circulating tumor DNA and circulating tumor cells testing investigational for all indications covered in this general policy, though specific FDA-approved companion diagnostic tests for targeted therapies are covered under separate cancer-specific policies. The policy excludes many common clinical applications which are addressed in other more permissive policies.",
          "coverageStatus": "restricts",
          "keyConditions": [
            "ctDNA and CTC testing considered investigational for indications in this policy",
            "FDA-approved companion diagnostic tests covered under separate cancer-specific policies",
            "Experimental or investigational procedures not covered per general exclusion",
            "Some plans may have contract exclusions for genetic testing or state mandates for biomarker coverage"
          ],
          "testsExplicitlyMentioned": [
            "Guardant360 CDx - covered as FDA-approved companion diagnostic for specific cancer types under separate policies",
            "FoundationOne Liquid CDx - covered as FDA-approved companion diagnostic for specific cancer types under separate policies"
          ],
          "significantChanges": [
            "Policy effective date January 1, 2025 suggests recent update",
            "Multiple related policies referenced indicating comprehensive restructuring of liquid biopsy coverage by cancer type"
          ],
          "confidence": 0.85
        },
        "extraction": {
          "stance": "denies",
          "stanceConfidence": 0.8,
          "cancerTypes": [
            "Breast",
            "CRC",
            "Lung",
            "Melanoma",
            "NSCLC",
            "Ovarian",
            "Pancreatic",
            "Prostate"
          ],
          "priorAuth": "unknown",
          "effectiveDate": null
        },
        "change": {
          "priority": "high",
          "changedHashes": [
            "new_document"
          ],
          "summary": "[HIGH] Changed: New document"
        },
        "delegationDetected": false,
        "artifactId": {
          "artifactId": "fepblue_fep-ctdna-204141_2026-02-05_1fd443453cb7",
          "artifactPath": "data/artifacts/fepblue/fepblue_fep-ctdna-204141_2026-02-05_1fd443453cb7",
          "contentHash": "1fd443453cb78540ab69d1a479f1c5569359edb8ef62c0ac6648bcac54432e36"
        },
        "pdfDiff": {
          "summary": "New document: 0 PLA codes, 0 CPT codes, 5 named tests.",
          "addedCodes": {
            "pla": [],
            "cpt": [],
            "hcpcs": [
              "S0500"
            ]
          },
          "removedCodes": {
            "pla": [],
            "cpt": [],
            "hcpcs": []
          }
        }
      },
      "status": "ignored"
    },
    {
      "submissionId": "sub-2026-mlg093htetn4",
      "source": "payers",
      "type": "payer_policy_update",
      "title": "Molina Healthcare: Genetic Testing (Policy No. 051) Updated",
      "summary": "This Molina Healthcare genetic testing policy establishes general criteria for genetic testing authorization but does not explicitly address ctDNA, liquid biopsy, or MRD testing despite having multiple MRD billing codes identified in the document. The policy appears to deny coverage for these tests based on the detected stance and lack of specific inclusion criteria.",
      "url": "https://www.molinaclinicalpolicy.com/molinaclinicalpolicy/-/media/Molina/PublicWebsite/PDF/Common/Molina-Clinical-Policy/Genetic-Testing_R.pdf",
      "detectedAt": "2026-02-05T20:09:43.352Z",
      "triageHint": {
        "daemonScore": 3,
        "reason": "",
        "suggestedAction": "coverage_update",
        "suggestedTestName": null,
        "confidence": 0.35
      },
      "metadata": {
        "payerId": "molina",
        "payerName": "Molina Healthcare",
        "policyId": "molina-genetic-testing-051",
        "policyName": "Genetic Testing (Policy No. 051)",
        "policyType": "molecular_oncology",
        "contentType": "pdf",
        "testsFound": [],
        "isNewPolicy": true,
        "analysis": {
          "summary": "This Molina Healthcare genetic testing policy establishes general criteria for genetic testing authorization but does not explicitly address ctDNA, liquid biopsy, or MRD testing despite having multiple MRD billing codes identified in the document. The policy appears to deny coverage for these tests based on the detected stance and lack of specific inclusion criteria.",
          "coverageStatus": "denies",
          "keyConditions": [
            "Test must be ordered by practitioner within scope of practice or medical geneticist",
            "Must meet specific criteria based on type of genetic testing requested",
            "For cancer-related testing, condition-specific MCG guidelines should be followed where they exist",
            "Mandatory biomarker coverage and state legal requirements may supersede this policy"
          ],
          "testsExplicitlyMentioned": [],
          "significantChanges": [
            "Policy effective date of 2026-01-01 suggests this is a future update",
            "Multiple MRD billing codes present (0239U, 0306U, 0340U, 0356U, 0364U, 0372U, 0378U, 0421U, 0425U, 0464U, 81599) but no explicit coverage criteria provided"
          ],
          "confidence": 0.7
        },
        "extraction": {
          "stance": "denies",
          "stanceConfidence": 0.7,
          "cancerTypes": [
            "All",
            "Ovarian"
          ],
          "priorAuth": "unknown",
          "effectiveDate": "2026-01-01"
        },
        "change": {
          "priority": "high",
          "changedHashes": [
            "new_document"
          ],
          "summary": "[HIGH] Changed: New document"
        },
        "delegationDetected": false,
        "artifactId": {
          "artifactId": "molina_molina-genetic-testing-051_2026-02-05_043afefa80a8",
          "artifactPath": "data/artifacts/molina/molina_molina-genetic-testing-051_2026-02-05_043afefa80a8",
          "contentHash": "043afefa80a865f085cd8f1505f7b0e105282889a12a0440fb808752020f9038"
        },
        "pdfDiff": {
          "summary": "New document: 357 PLA codes, 272 CPT codes, 19 named tests.",
          "addedCodes": {
            "pla": [
              "0001U",
              "0003U",
              "0005U",
              "0007U",
              "0008U",
              "0009U",
              "0010U",
              "0016U",
              "0017U",
              "0018U",
              "0019U",
              "0021U",
              "0022U",
              "0023U",
              "0026U",
              "0027U",
              "0029U",
              "0030U",
              "0031U",
              "0032U",
              "0033U",
              "0034U",
              "0035U",
              "0036U",
              "0037U",
              "0040U",
              "0045U",
              "0046U",
              "0047U",
              "0048U",
              "0049U",
              "0050U",
              "0055U",
              "0058U",
              "0059U",
              "0060U",
              "0067U",
              "0069U",
              "0070U",
              "0071U",
              "0072U",
              "0073U",
              "0074U",
              "0075U",
              "0076U",
              "0079U",
              "0080U",
              "0084U",
              "0087U",
              "0088U",
              "0089U",
              "0090U",
              "0091U",
              "0092U",
              "0094U",
              "0101U",
              "0102U",
              "0103U",
              "0105U",
              "0108U",
              "0109U",
              "0111U",
              "0112U",
              "0113U",
              "0114U",
              "0115U",
              "0117U",
              "0118U",
              "0119U",
              "0120U",
              "0129U",
              "0130U",
              "0131U",
              "0132U",
              "0133U",
              "0134U",
              "0135U",
              "0136U",
              "0137U",
              "0138U",
              "0140U",
              "0141U",
              "0142U",
              "0152U",
              "0153U",
              "0154U",
              "0155U",
              "0156U",
              "0157U",
              "0158U",
              "0159U",
              "0160U",
              "0161U",
              "0162U",
              "0163U",
              "0166U",
              "0169U",
              "0170U",
              "0171U",
              "0172U",
              "0173U",
              "0174U",
              "0175U",
              "0177U",
              "0179U",
              "0180U",
              "0181U",
              "0182U",
              "0183U",
              "0184U",
              "0185U",
              "0186U",
              "0187U",
              "0188U",
              "0189U",
              "0190U",
              "0191U",
              "0192U",
              "0193U",
              "0194U",
              "0195U",
              "0196U",
              "0197U",
              "0198U",
              "0199U",
              "0200U",
              "0201U",
              "0202U",
              "0203U",
              "0205U",
              "0206U",
              "0207U",
              "0209U",
              "0211U",
              "0212U",
              "0213U",
              "0214U",
              "0215U",
              "0216U",
              "0217U",
              "0218U",
              "0219U",
              "0220U",
              "0221U",
              "0222U",
              "0223U",
              "0225U",
              "0228U",
              "0229U",
              "0230U",
              "0231U",
              "0232U",
              "0233U",
              "0234U",
              "0235U",
              "0236U",
              "0237U",
              "0238U",
              "0239U",
              "0242U",
              "0244U",
              "0245U",
              "0246U",
              "0249U",
              "0250U",
              "0252U",
              "0253U",
              "0254U",
              "0258U",
              "0260U",
              "0261U",
              "0262U",
              "0263U",
              "0264U",
              "0265U",
              "0266U",
              "0267U",
              "0268U",
              "0269U",
              "0270U",
              "0271U",
              "0272U",
              "0273U",
              "0274U",
              "0276U",
              "0277U",
              "0278U",
              "0279U",
              "0280U",
              "0281U",
              "0282U",
              "0285U",
              "0286U",
              "0287U",
              "0288U",
              "0289U",
              "0290U",
              "0291U",
              "0292U",
              "0293U",
              "0294U",
              "0295U",
              "0296U",
              "0297U",
              "0298U",
              "0299U",
              "0300U",
              "0301U",
              "0302U",
              "0306U",
              "0307U",
              "0308U",
              "0309U",
              "0310U",
              "0312U",
              "0313U",
              "0314U",
              "0315U",
              "0317U",
              "0318U",
              "0319U",
              "0320U",
              "0321U",
              "0322U",
              "0323U",
              "0326U",
              "0327U",
              "0329U",
              "0330U",
              "0331U",
              "0332U",
              "0333U",
              "0334U",
              "0335U",
              "0336U",
              "0337U",
              "0338U",
              "0339U",
              "0340U",
              "0341U",
              "0342U",
              "0343U",
              "0345U",
              "0347U",
              "0348U",
              "0349U",
              "0350U",
              "0355U",
              "0356U",
              "0360U",
              "0362U",
              "0363U",
              "0364U",
              "0365U",
              "0366U",
              "0367U",
              "0368U",
              "0371U",
              "0372U",
              "0375U",
              "0378U",
              "0379U",
              "0387U",
              "0388U",
              "0389U",
              "0390U",
              "0391U",
              "0392U",
              "0393U",
              "0394U",
              "0395U",
              "0398U",
              "0399U",
              "0400U",
              "0401U",
              "0403U",
              "0404U",
              "0405U",
              "0406U",
              "0407U",
              "0409U",
              "0410U",
              "0411U",
              "0412U",
              "0413U",
              "0414U",
              "0415U",
              "0417U",
              "0418U",
              "0419U",
              "0420U",
              "0421U",
              "0422U",
              "0423U",
              "0424U",
              "0425U",
              "0426U",
              "0433U",
              "0434U",
              "0436U",
              "0437U",
              "0438U",
              "0439U",
              "0440U",
              "0444U",
              "0449U",
              "0452U",
              "0453U",
              "0454U",
              "0458U",
              "0460U",
              "0461U",
              "0463U",
              "0464U",
              "0465U",
              "0466U",
              "0467U",
              "0469U",
              "0470U",
              "0471U",
              "0472U",
              "0473U",
              "0474U",
              "0475U",
              "0476U",
              "0477U",
              "0478U",
              "0480U",
              "0481U",
              "0484U",
              "0485U",
              "0486U",
              "0487U",
              "0488U",
              "0489U",
              "0490U",
              "0491U",
              "0492U",
              "0493U",
              "0494U",
              "0495U",
              "0496U",
              "0497U",
              "0498U",
              "0499U",
              "0500U",
              "0501U",
              "0502U",
              "0503U",
              "0504U",
              "0505U",
              "0506U",
              "0507U",
              "0508U",
              "0509U",
              "0510U",
              "0516U"
            ],
            "cpt": [
              "81106",
              "81107",
              "81108",
              "81109",
              "81110",
              "81111",
              "81112",
              "81170",
              "81173",
              "81174",
              "81175",
              "81176",
              "81177",
              "81178",
              "81179",
              "81180",
              "81181",
              "81182",
              "81183",
              "81184",
              "81185",
              "81186",
              "81187",
              "81188",
              "81189",
              "81190",
              "81191",
              "81192",
              "81193",
              "81194",
              "81200",
              "81201",
              "81202",
              "81203",
              "81204",
              "81205",
              "81206",
              "81207",
              "81208",
              "81209",
              "81210",
              "81212",
              "81215",
              "81216",
              "81217",
              "81218",
              "81219",
              "81220",
              "81221",
              "81222",
              "81223",
              "81224",
              "81225",
              "81226",
              "81227",
              "81228",
              "81229",
              "81230",
              "81231",
              "81232",
              "81233",
              "81234",
              "81235",
              "81236",
              "81237",
              "81238",
              "81239",
              "81240",
              "81241",
              "81242",
              "81243",
              "81244",
              "81245",
              "81246",
              "81247",
              "81248",
              "81249",
              "81250",
              "81251",
              "81252",
              "81253",
              "81254",
              "81255",
              "81256",
              "81257",
              "81258",
              "81259",
              "81260",
              "81261",
              "81262",
              "81263",
              "81264",
              "81265",
              "81266",
              "81267",
              "81268",
              "81269",
              "81270",
              "81271",
              "81272",
              "81273",
              "81274",
              "81275",
              "81276",
              "81277",
              "81278",
              "81279",
              "81283",
              "81284",
              "81285",
              "81286",
              "81287",
              "81288",
              "81289",
              "81290",
              "81291",
              "81292",
              "81293",
              "81294",
              "81295",
              "81296",
              "81297",
              "81298",
              "81299",
              "81300",
              "81301",
              "81302",
              "81303",
              "81304",
              "81305",
              "81306",
              "81307",
              "81308",
              "81309",
              "81310",
              "81311",
              "81312",
              "81313",
              "81314",
              "81315",
              "81316",
              "81317",
              "81318",
              "81319",
              "81320",
              "81321",
              "81322",
              "81323",
              "81324",
              "81325",
              "81326",
              "81327",
              "81328",
              "81329",
              "81330",
              "81331",
              "81332",
              "81333",
              "81334",
              "81335",
              "81336",
              "81337",
              "81338",
              "81339",
              "81340",
              "81341",
              "81342",
              "81343",
              "81344",
              "81345",
              "81346",
              "81347",
              "81348",
              "81349",
              "81350",
              "81351",
              "81352",
              "81353",
              "81354",
              "81355",
              "81357",
              "81360",
              "81361",
              "81362",
              "81363",
              "81364",
              "81370",
              "81371",
              "81372",
              "81373",
              "81374",
              "81375",
              "81376",
              "81377",
              "81378",
              "81379",
              "81380",
              "81381",
              "81382",
              "81383",
              "81400",
              "81401",
              "81402",
              "81403",
              "81404",
              "81405",
              "81406",
              "81407",
              "81408",
              "81410",
              "81411",
              "81412",
              "81413",
              "81414",
              "81415",
              "81416",
              "81417",
              "81418",
              "81419",
              "81420",
              "81422",
              "81425",
              "81426",
              "81427",
              "81430",
              "81431",
              "81432",
              "81434",
              "81435",
              "81437",
              "81439",
              "81440",
              "81441",
              "81442",
              "81443",
              "81445",
              "81448",
              "81449",
              "81450",
              "81451",
              "81455",
              "81456",
              "81457",
              "81458",
              "81459",
              "81460",
              "81462",
              "81463",
              "81464",
              "81465",
              "81470",
              "81471",
              "81541",
              "81542",
              "81546",
              "81551",
              "81552",
              "81554",
              "81595",
              "81599",
              "86386",
              "88120",
              "88121",
              "88364",
              "88365",
              "88366",
              "88367",
              "88368",
              "88369",
              "88373",
              "88374",
              "88377"
            ],
            "hcpcs": [
              "G9143",
              "S0265",
              "S3840",
              "S3841",
              "S3842",
              "S3844",
              "S3845",
              "S3846",
              "S3849",
              "S3850",
              "S3852",
              "S3853",
              "S3861",
              "S3865",
              "S3866",
              "S3870"
            ]
          },
          "removedCodes": {
            "pla": [],
            "cpt": [],
            "hcpcs": []
          }
        }
      },
      "status": "ignored"
    },
    {
      "submissionId": "sub-2026-mlg093htvuw1",
      "source": "payers",
      "type": "payer_policy_update",
      "title": "Kaiser Permanente: Genetic Screening and Testing Clinical Review Criteria Updated",
      "summary": "The policy covers specific FDA-approved liquid biopsy tests like FoundationOne Liquid CDx and Guardant360 CDx for Medicare members through established Medicare guidelines, but does not explicitly address MRD testing or most ctDNA monitoring applications. For non-Medicare members, coverage appears more restrictive with limited mention of liquid biopsy testing outside of advanced cancer NGS panels.",
      "url": "https://wa-provider.kaiserpermanente.org/static/pdf/hosting/clinical/criteria/pdf/genetic_screening.pdf",
      "detectedAt": "2026-02-05T20:09:43.354Z",
      "triageHint": {
        "daemonScore": 8,
        "reason": "",
        "suggestedAction": "coverage_update",
        "suggestedTestName": null,
        "confidence": 0.85
      },
      "metadata": {
        "payerId": "kaiser",
        "payerName": "Kaiser Permanente",
        "policyId": "kaiser-wa-genetic-screening",
        "policyName": "Genetic Screening and Testing Clinical Review Criteria",
        "policyType": "molecular_oncology",
        "contentType": "pdf",
        "testsFound": [
          "mrd-7",
          "mrd-19",
          "trm-1",
          "tds-1",
          "ecd-2"
        ],
        "isNewPolicy": true,
        "analysis": {
          "summary": "The policy covers specific FDA-approved liquid biopsy tests like FoundationOne Liquid CDx and Guardant360 CDx for Medicare members through established Medicare guidelines, but does not explicitly address MRD testing or most ctDNA monitoring applications. For non-Medicare members, coverage appears more restrictive with limited mention of liquid biopsy testing outside of advanced cancer NGS panels.",
          "coverageStatus": "restricts",
          "keyConditions": [
            "Must meet Medicare MolDX program criteria for covered tests",
            "FDA approval required (specific CPT codes listed for approved tests)",
            "Advanced cancer diagnosis required for somatic testing",
            "Must meet medical necessity criteria",
            "Preferred lab networks required for non-Medicare members"
          ],
          "testsExplicitlyMentioned": [
            "FoundationOne Liquid CDx (0239U) - covered for Medicare with conditions",
            "Guardant360 CDx (0242U) - covered for Medicare with conditions",
            "Galleri mentioned in colorectal screening context",
            "Signatera and ClonOSEQ not explicitly covered"
          ],
          "significantChanges": [
            "Policy effective 2022-01-01 shows established Medicare coverage for specific liquid biopsy CDx tests",
            "Clear separation between Medicare coverage (more permissive for approved tests) and commercial coverage (more restrictive)"
          ],
          "confidence": 0.85
        },
        "extraction": {
          "stance": "denies",
          "stanceConfidence": 0.8,
          "cancerTypes": [],
          "priorAuth": "not_required",
          "effectiveDate": "2022-01-01"
        },
        "change": {
          "priority": "high",
          "changedHashes": [
            "new_document"
          ],
          "summary": "[HIGH] Changed: New document"
        },
        "delegationDetected": false,
        "artifactId": {
          "artifactId": "kaiser_kaiser-wa-genetic-screening_2026-02-05_d4661e52e8db",
          "artifactPath": "data/artifacts/kaiser/kaiser_kaiser-wa-genetic-screening_2026-02-05_d4661e52e8db",
          "contentHash": "d4661e52e8db68621606940d08719bdfc89b4c85c2c0b91650acd40e78bf008e"
        },
        "pdfDiff": {
          "summary": "New document: 21 PLA codes, 70 CPT codes, 17 named tests.",
          "addedCodes": {
            "pla": [
              "0018U",
              "0022U",
              "0026U",
              "0034U",
              "0037U",
              "0060U",
              "0111U",
              "0169U",
              "0172U",
              "0211U",
              "0236U",
              "0239U",
              "0242U",
              "0245U",
              "0339U",
              "0364U",
              "0422U",
              "0473U",
              "0485U",
              "0523U",
              "0543U"
            ],
            "cpt": [
              "80299",
              "81162",
              "81210",
              "81211",
              "81212",
              "81213",
              "81220",
              "81225",
              "81226",
              "81227",
              "81228",
              "81229",
              "81232",
              "81235",
              "81247",
              "81249",
              "81275",
              "81276",
              "81283",
              "81291",
              "81311",
              "81328",
              "81329",
              "81331",
              "81335",
              "81336",
              "81337",
              "81346",
              "81350",
              "81355",
              "81381",
              "81401",
              "81403",
              "81405",
              "81406",
              "81420",
              "81422",
              "81443",
              "81445",
              "81457",
              "81458",
              "81459",
              "81462",
              "81463",
              "81464",
              "81479",
              "81507",
              "81518",
              "81519",
              "81520",
              "81522",
              "81535",
              "81536",
              "81540",
              "81541",
              "81546",
              "81551",
              "82148",
              "84433",
              "84999",
              "85576",
              "87900",
              "87901",
              "87906",
              "87999",
              "88360",
              "88374",
              "88377",
              "88381",
              "89240"
            ],
            "hcpcs": [
              "G0452",
              "G9143",
              "S3852",
              "S3854"
            ]
          },
          "removedCodes": {
            "pla": [],
            "cpt": [],
            "hcpcs": []
          }
        }
      },
      "status": "ignored"
    }
  ],
  "stats": {
    "total": 64,
    "bySource": {
      "cms": 3,
      "vendor": 9,
      "payers": 52
    },
    "byConfidence": {
      "high": 41,
      "medium": 7,
      "low": 16
    }
  }
}